University of South Florida

Digital Commons @ University of South Florida
Graduate Theses and Dissertations

Graduate School

7-26-2012

Medication Monitoring in the Schools: An Investigation of Current
Practices of Florida School Psychologists
Jason Hangauer
University of South Florida, jhangaue@health.usf.edu

Follow this and additional works at: https://digitalcommons.usf.edu/etd
Part of the American Studies Commons, Education Commons, Education Policy Commons, and the
Psychology Commons

Scholar Commons Citation
Hangauer, Jason, "Medication Monitoring in the Schools: An Investigation of Current Practices of Florida
School Psychologists" (2012). Graduate Theses and Dissertations.
https://digitalcommons.usf.edu/etd/4065

This Dissertation is brought to you for free and open access by the Graduate School at Digital Commons @
University of South Florida. It has been accepted for inclusion in Graduate Theses and Dissertations by an
authorized administrator of Digital Commons @ University of South Florida. For more information, please contact
scholarcommons@usf.edu.

Medication Monitoring in the Schools:
An Investigation of Current Practices of Florida School Psychologists

by

Jason D. Hangauer

A dissertation submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
Department of Psychological and Social Foundations
College of Education
University of South Florida

Major Professor: Kathy L. Bradley-Klug, Ph.D.
Tiffany Chenneville, Ph.D.
Robert Dedrick, Ph.D.
Julia Ogg, Ph.D.

Date of Approval:
July 26, 2012

Keywords: psychotropic medications, effects, behavioral functioning, youth
Copyright © 2012, Jason D. Hangauer

Dedication

This manuscript is dedicated to the individuals who have provided me with
encouragement and support not only in the creation of this work but also throughout all
of my education. I would like to give a special thanks to both my parents who have
helped provide values of working hard, instilling integrity in all endeavors, and following
through even when it is difficult. I also would like to thank my family as a whole who has
always put an emphasis on education and the pursuit of knowledge. To all my friends
and extended family, I have been very blessed with your support throughout my life.

Acknowledgements
I would like to thank my committee members for their expertise in developing this
study as well as the many hours of their time spent in mentoring and providing expertise
in evaluating each aspect of this study with scientific rigor. I would like to give a special
thank you to Dr. Kathy Bradley-Klug, the chairperson of my committee for her great deal
of mentorship and many hours spent helping make this project a reality. From when I
started my graduate education, Dr. Bradley-Klug has helped me grow as a researcher as
well as a practitioner of school psychology. Additionally, the faculty of the School
Psychology Program deserves a special thank you for also helping to mentor me
throughout my graduate education. I feel their expertise and mentorship helped me grow
immensely and develop a passion for helping children and adolescents by using evidencebased practices. I also would like to thank Dr. Kathleen Armstrong who has greatly
helped me over the latter portion of my graduate training putting all the knowledge I
learned into practice. Without her mentorship and guidance I would not be where I am
professionally today.

Table of Contents
List of Tables

iii

Abstract

v

Chapter One: Introduction
Statement of the Problem
Effects and Risks of Psychotropic Medications on Behavioral
and Social Functioning
Medication Monitoring in the Schools
Rationale for the Study
Purpose of the Study
Research Questions
Significance of the Study

1
1
3
4
6
7
7
8

Chapter Two: Review of the Literature
Overview
Prevalence of Children and Adolescents Prescribed Psychotropic
Medications
Risks of Psychotropic Medication Use in Children and Adolescents
Effects of Psychotropic Medications on Academic, Behavioral, and Social
Functioning
Legal and Ethical Issues in Medication Utilization in Public Schools
Medication Monitoring Practices in Public Schools
Collaboration between School Personnel and Medical Providers
Role of the School Psychologist
Conclusions

10
10

Chapter Three: Method
Introduction
Participants
Respondent Information
Demographic Information
Materials
Procedures

48
48
48
49
50
53
55

Chapter Four: Results
Treatment of the Data

61
61
i

10
18
20
32
34
38
39
47

Research Question 1
Research Question 2
Research Question 3
Research Question 3a
Research Question 3b
Research Question 3c
Research Question 3d
Research Question 4
Research Question 5
Research Question 6
Additional Information
Predictors of Medication Monitoring
Types of Disorders School Psychologists Monitor Medications
Summary

63
64
67
68
69
71
72
73
75
80
83
83
86
89

Chapter 5: Discussion
Summary of the Study
Research Questions 1 and 2
Research Question 3
Research Question 4
Research Question 5
Research Question 6
Additional Information
Predictors of Medication Monitoring
Types of Disorders School Psychologists Monitor Medications
Implications for Practice
Limitations
Future Directions
Final Thoughts

91
91
91
94
98
100
104
106
106
107
109
111
113
114

References

115

Appendices
Appendix A: Cover Letter to Participants
Appendix B: Follow-up Cover Letter to Participants
Appendix C: Survey
Appendix D: Institutional Review Board Approval Letter

122
123
125
127
134

ii

List of Tables
Table 1

Psychotropic Medications by Disorder:
Evidence of Efficacy and Side Effects

22

Table 2

Respondent Data

50

Table 3

Comparison of School Psychologists’ Demographic
Categories of Current Study to NASP Membership (2010)

52

Descriptive Statistics of School Psychologists’ Beliefs Related to
Medication Monitoring (n =140)

63

Response to Role of School Psychologists in Medication
Monitoring (n =140)

63

Spearman’s Rho Correlation between Beliefs in Medication
Monitoring and Actual Reported Practices (n = 77)

65

Independent Samples T-test Examining Beliefs Regarding
Medication Monitoring and Reported Involvement in Medication
Monitoring (n = 137)

66

Table 8

Frequency of Medication Monitoring Practices (n = 77)

69

Table 9

Frequency of Sharing Medication Monitoring Information and with
Whom it is Shared (n = 77)

72

Table 4

Table 5

Table 6

Table 7

iii

Table 10

Percentage of Respondents with Training in Medication
Monitoring (n = 140)

73

Table 11

Descriptive Statistics of Types of Medication Monitoring Training
(n =77)

74

Table 12

Perceptions of Barriers to Medication Monitoring (n = 140)

78

Table 13

Perceptions of Facilitators to Medication Monitoring (n = 109)

79

Table 14

Intercorrelations between Demographic Variables and Medication
Monitoring Practices

81

Simultaneous Regression Analysis for Demographic Variables and
Training Predicting Medication Monitoring Practices (n = 51)

86

Disorders for which School Psychologists Report Monitoring
Medication in the Past Year (n =77)

88

Table 15

Table 16

iv

Abstract
Prevalence rates of youth prescribed psychotropic medications have risen dramatically
over the past decade. Many of these medications are prescribed to treat symptoms of a
disorder that occur in the school setting. Some medications have negative side effects
that can inhibit academic and social performance. School psychologists have been
identified as professionals who are equipped to assist in monitoring both the beneficial
and negative effects of medications for youth attending school. This study investigated
the practices, training, types of disorders for which medication monitoring occurs,
facilitators, and barriers to school psychologists engaging in medication monitoring in the
schools. Survey data from 166 members of the Florida Association of School
Psychologists were collected and analyzed. Seventy four percent of respondents
endorsed medication monitoring as an appropriate role for school psychologists.
Approximately half of the respondents in this study reported engaging in medication
monitoring over the past school year. Over half the sample reported receiving training
related to medication monitoring. Weak relationships were found among demographic
and training variables and reported medication monitoring practices. Additionally, none
of the interactions between demographic, professional background, and training variables
was predictive of medication monitoring practices. Implications of these findings are
discussed in relation to developing strategies to promote the medication monitoring
practices of school psychologists.
v

Chapter One
Introduction
Statement of the Problem
Utilization rates of psychotropic medications, particularly in youth, have
increased dramatically over the past decade. Zito (2003) reported a three-fold increase in
the overall utilization rates of psychotropic medications in children and adolescents aged
4-19 years from 1987-1996. A 10-fold increase was observed for antidepressant
medications for children and adolescents insured by Medicaid, and a five-fold increase
was observed across children and adolescents insured by health maintenance
organizations (HMOs [Zito, 2003]). Utilization rates of psychotropic medications
prescribed to treat disorders such as Autism Spectrum Disorder, Asperger’s syndrome,
Obsessive Compulsive Disorder, and Conduct Disorder also have increased dramatically
over the past decade (Abrams, Flood, & Phelps, 2006). Research targeting children
receiving special education services found that 39% of these children are prescribed a
psychotropic medication including stimulants, antipsychotics, antidepressants, and
antihypertensive medications to inhibit externalizing behaviors (Mattison, 1999).
Additionally, Mattison reported 17% of students receiving special education services
were administered multiple medications.
Given these high utilization rates of psychotropic medications among school-aged
youth, monitoring the effects of these medications is needed. Psychotropic medications
are typically prescribed to treat both externalizing and internalizing symptoms of
1

emotional and behavioral disorders such as Attention-Deficit/Hyperactivity Disorder
(ADHD), Oppositional Defiant Disorder, anxiety disorders, depressive disorders, and
autism spectrum disorders (American Psychological Association [APA] Working Group
on Psychoactive Medications for Children & Adolescents, 2006).
Many psychotropic medications have potentially serious side effects in youth.
Specifically, the Food and Drug Administration (FDA) issued “black box” warnings on
certain classes of medications prescribed to children and adolescents under 18 years of
age, warning of serious potential side effects. The black box warning is the strongest
warning available from the FDA. Side effects of some psychotropic medications may
include suicidal ideation, acute seizures, cognitive/psychomotor impairment, and sudden
increases or decreases in blood pressure resulting in acute episodes of hypotension or
hypertension which can cause sudden fainting or headaches and blurred vision (APA
Working Group, 2006; FDA, 2005).
Of additional concern is the fact that many psychotropic medications prescribed
to youth are only approved by the FDA for use with adults; in other words, they are being
used off-label or without documented efficacy in pediatric populations (Bush, 2006). The
common practice in pediatrics of extrapolating adult doses of medications approved by
the FDA to children is fraught with problems (Bush, 2006). For instance, drug
absorption, metabolism, and secretion in children and adolescent’s bodies can be
markedly different than adults (Christensen, Helms, & Chesney, 1999). As a result, close
monitoring of the effects (both beneficial and detrimental) of psychotropic medications is
needed to ensure children and adolescents’ response to medication does not impede
academic and/or social-emotional functioning (Christensen et al., 1999).
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Effects and Risks of Psychotropic Medications on Behavioral and Social
Functioning
The APA Working Group (2006) offers the most up-to-date, comprehensive
review of psychotropic medications and effects on childhood disorders. The disorders
reviewed include: (a) Attention-Deficit/Hyperactivity Disorder (ADHD); (b)
Oppositional Defiant Disorder (ODD); (c) Conduct Disorder; (CD); (d) Tourette and tic
disorders; (e) Obsessive–Compulsive Disorder (OCD); (f) anxiety disorders; (h)
depressive disorders; (i) bipolar disorder; (j) schizophrenia; and (k) autism spectrum
disorder. The effects of some medications can be profound (e.g., permanent involuntary
motor tics which resemble Parkinsonian symptoms known as extrapyramidal symptoms)
while polypharmacy, the practice of combining different classes of medications to
diminish side effects of other medications, can have potentially dangerous health risks as
well as unpredictable effects on social and academic functioning (Christensen et al.,
1999).
Combining multiple psychotropic medications to counteract side effects is
commonplace (Christensen et al., 1999). For example, it is common for children taking
stimulant medications to also be prescribed a medication off-label (e.g., Clonidine or
Tenex) to counteract insomnia. However, many medications prescribed to counteract
effects of stimulant medications can have significant and sudden side effects for which
careful monitoring is required. For example, Clonidine, an anti-hypertensive medication
commonly prescribed off-label to treat insomnia in children taking stimulants, can
produce sudden drops in blood pressure otherwise known as hypotension (Christensen et
al., 1999). Alternatively, if this medication is suddenly stopped (e.g., parent or school
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personnel forget to administer the medication) a dangerous sudden rise in blood pressure
(hypertension) may occur (Kratochvil, Lake, Pliszka, & Walkup, 2005). Many classes of
medication have side effects (e.g., headaches, nausea, anxious symptoms, loss of
academic skills due to medication side effects, and lethargy) that can negatively impact
school functioning (APA Working Group, 2006). Further, different doses of medications
can mitigate negative side effects significantly once a proper dosage is found. Lastly,
there is a paucity of data related to appropriate dosages as well as long-term safety of
medication prescribed to youth (APA Working Group, 2006).
Medication Monitoring in Schools
Public school personnel are playing an ever increasing role in pharmacological
treatment of school-aged children. Non-medical school personnel (e.g., secretaries and
instructional assistants) are required to dispense psychotropic medications including
controlled medications with little or no supervision, particularly in rural areas of the
country (DuPaul & Carlson, 2005). As a result, the probability of medication errors such
as the inability to determine if a child took the medication, overdosing, and giving the
incorrect medication to a student increases (DuPaul et al., 2005). Monitoring the
effectiveness as well as negative side effects of medications is needed. The school
psychologist has been identified as a professional, positioned in the school setting, who
possesses unique training that is well-suited for medication monitoring. Specifically,
school psychologists’ knowledge and skills in consultation, problem solving, behavioral
observations, intervention planning, and progress monitoring position them as ideal
professionals within the education system to assist in the collection of data for the
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purposes of progress monitoring the effects of medication (Grier & Bradley-Klug, in
press; Power, DuPaul, Shapiro, & Kazak, 2003; Stoner, Carey, Ikeda, & Shinn, 1994).
A study conducted by Guerasko-Moore, DuPaul, and Power (2005) examined
school psychologists’ medication monitoring practices for children and adolescents being
treated for symptoms related to ADHD. The researchers examined perceptions, training,
practices, and perceived barriers to medication monitoring. Results indicated 54.5% of
school psychologists reported engaging in medication monitoring and the majority
reported this was an important professional role. Teacher and parent rating forms,
interviews, direct observation, and review of work samples were perceived by school
psychologists as the most effective, acceptable, and feasible monitoring methods. The
majority of school psychologists (58.1%) reported not receiving formal training in
medication monitoring. Additionally, receiving formal training (e.g., university-based
class) on medication monitoring significantly increased the likelihood a school
psychologist reported engaging in medication monitoring. The greatest facilitator of
medication monitoring was teacher support. Barriers to medication monitoring were time
and accessibility of physicians to collaborate. Although this study provides information
regarding the medication practices of school psychologists related to youth with ADHD,
additional research is needed to determine whether these findings extend to the
monitoring of other medications frequently prescribed to school-age children and
adolescents.
Facilitating and maintaining collaborative partnerships between school personnel
and primary care providers (e.g., pediatricians) is another important aspect of medication
monitoring (Grier & Bradley-Klug, in press). Haile-Mariam, Bradley-Johnson, and
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Johnson (2002) found the majority of physicians (81%) were interested in more
information from schools related to behavioral observations, academic performance, and
intellectual functioning. Additionally, the majority of physicians reported the type of
information they often receive (e.g., lengthy psychoeducational reports) is not useful due
to time constraints of the physician. Wodrich and Landau (1999) recommend building a
working relationship between primary care pediatrics and school psychologists,
particularly for children with medical concerns. Developing concise methods of
conveying information that respects both parties’ time constraints is an important
consideration when forging working alliances. School psychologists and pediatricians
can develop working alliances for school-age children taking medications that may
impact academic as well as social-emotional functioning.
Rationale for the Study
Current research indicates the utilization rates of psychotropic medications
prescribed to school-age children is on the rise (Abrams, Flood, & Phelps, 2006; Zito,
2003). Many of the current psychotropic medications being used in pediatric populations
have no randomized controlled trials demonstrating their efficacy in this population. As a
result, many psychotropic medications are approved for use in adults but are prescribed
off-label to children. In many cases, the side-effects and long-term impact on academic
and social-emotional functioning in children have not been studied. Some effects are
directly linked to academic performance (e.g., memory loss, loss of academic skills or
cognitive/psychomotor impairment) which may go unnoticed by other school personnel
without training in assessment and progress monitoring. Therefore, examining how
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school personnel, specifically school psychologists, can assist in monitoring the effects of
medications on youth during school hours is needed.
Purpose of the Study
This study sought to address gaps in the literature related to school psychologists’
medication monitoring practices for the most commonly prescribed medications
including stimulants, antipsychotics, Alpha 2 agonists, typical and atypical neuroleptics,
selective seratonin reuptake inhibitors (SSRIs), tricyclics, and benzodiazepines.
Although research has found over half of school psychologists surveyed reported
engaging in medication monitoring as part of their practice (Gureasko-Moore, et al.,
2005), research to date has not examined the medication monitoring practices of school
psychologists beyond medications used to treat symptoms of ADHD. Current utilization
rates suggest a significant number of youth in our schools are prescribed a variety of
psychotropic medications to treat diverse symptoms of the most common disorders of
youth (e.g., anxiety disorders, depressive disorders, ODD, autism spectrum disorders
[Abrams, Flood, & Phelps, 2006; Mattison, 1999]).
Research Questions
1. Do school psychologists believe medication monitoring is a role in which they
should be engaged?
2. What is the relationship between school psychologists
beliefs regarding medication monitoring as part of their role and their likelihood
of engaging in medication monitoring in practice?
3. What are the current medication monitoring practices of school psychologists?
a) What types of data are collected when engaged in medication monitoring?
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b) What is the frequency (e.g., daily, weekly, or monthly) that medication
monitoring data are collected?
c) What is the frequency (e.g, daily, weekly, or monthly) that medication
monitoring data are shared?
d) With whom is medication monitoring information shared (e.g.,
primary care provider, school nurse, teachers, parents)?
4. What types of training (pre-service vs. in-service) do school psychologists receive
in the practice of medication monitoring?
5. What are the perceived barriers and facilitators to medication monitoring?
6. What is the direction and strength of the relationship between geographic
location, degree level, training program philosophy, type of school served, types
of training reported related to medication monitoring and frequency of medication
monitoring by school psychologists?
Significance of the Study
This study built on existing literature that examined medication monitoring
practices of school psychologists related to stimulant medications to treat symptoms of
ADHD (Gureasko-Moore et al., 2005). Identification of medication monitoring practices
currently employed, types of training school psychologists have received related to
medication monitoring, and what methods for monitoring medications (e.g., behavioral
observation, behavior rating scales, review of academic work) school psychologists feel
are the most effective and acceptable in their practice were examined. This information
will inform both pre-service and in-service practices related to medication monitoring.
Additionally, identification of the facilitators and barriers to monitoring medications
(e.g., time, training, and support from teachers) can be used to assist school psychologists
8

in implementing systems-wide efforts to more effectively engage in medication
monitoring.
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Chapter Two
Review of Related Literature
Overview
This chapter provides a review of the literature relevant to this study. The present
study examined medication monitoring practices of school psychologists for students
currently prescribed psychotropic medications. Specifically, a survey was utilized to
examine current practice, training (pre-service and in-service), perceived effectiveness of
specific procedures, and perceived barriers related to medication monitoring. A literature
review was conducted to examine the current state of research on medication monitoring
by school psychologists. This review of relevant literature is divided into seven primary
areas, including: 1) prevalence rates of children and adolescents prescribed psychotropic
medications; 2) risks of psychotropic medication use in children and adolescents; 3)
effects of psychotropic medications on academic and social functioning; 4) role of the
public school personnel in medication administration; 5) legal and ethical issues, 6)
medication monitoring practices in public schools; and 7) role of the school psychologist
in medication monitoring.
Prevalence of Children and Adolescents Prescribed Psychotropic Medications
Current research is equivocal regarding the utilization rates of psychotropic
medications in youth populations. For the purposes of this literature review utilization
rates are defined as the overall percentage of psychotropic medication prescribed for use
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in a given population. Zuvekas, Vitiello, and Norquist (2006) examined trends in
utilization rates of stimulant medications in children ages 0-18 years in the United States.
Specifically, these researchers used the Medical Expenditure Panel Survey (MEPS), a
nationally representative sample of U.S. households from the years 1997-2002. The
MEPS is a household survey of health care use and costs conducted by the National
Center on Health Statistics. The overall response rate for years 1997-2002 was 66.4%.
Sample sizes for years 1997-2002 ranged from 7,235 to 11,713 randomly sampled
households. Data on prescription drug use were collected directly from households
responding to the survey. Results indicated the utilization rates of stimulant medication
use among children and adolescents under 19 years of age was 2.7% in 1997 and 2.9% in
2002. The researchers indicate this is not a statistically significant change over the five
year period. Use of stimulants was highest among 6-12 year olds at 4.8% in 2002 and
lowest among preschool aged children (under 6 years old) at 0.3% in 2002. Additionally,
the researchers found current use of stimulant medications was highest in males (4.0% in
2002) compared to 1.7% for females. Use of stimulant medications was also highest for
Caucasian children (3.6%), while 2.2% for African American children and 1.4% for
Hispanic children. Respondents who did not have insurance had lower stimulant
utilization rates (0.9%) than those with publicly funded health insurance (i.e., Medicaid)
(3.3%) or private health insurance (3.0%). Notably, the researchers also found variable
utilization rates of stimulant medications based on region. Specifically, the Southeast
region of the U.S. had utilization rates of 3.4% overall compared to the Western region of
the U.S. at 2.2%. Significant increases in utilization rates in the Northeast region of the
U.S., from 1.6% in 1997 to 2.7% in 2002 were reported.
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Overall, this survey examined utilization rates of stimulant medications in
children under 19 years of age across the U.S. The results indicated relatively stable
utilization rates with some regional differences (i.e, greater prevalence in the Southeast).
However, this study has limitations. Specifically, the study relied on participants’ selfreport to accurately recall information. It is possible that self-report bias could result in
under or over-reporting of stimulant utilization.
Other researchers have examined utilization rates for a variety of psychotropic
medications. Zito et al. (2003) conducted a study examining changes in the utilization
rates of psychotropic medications for children and adolescents over a 10-year period.
Specifically, these researchers used a population-based analysis of 900,000 children and
adolescents enrolled in two U.S. healthcare systems. Medicaid data from two states and
dispensing records from a large private health maintenance organization (HMO) were
utilized. The results found at least six percent of children and adolescents being served
by Medicaid and HMO insurance organizations had been prescribed a psychotropic
medication across all geographic areas of the U.S. Zito et al. (2003) reported a three-fold
increase in utilization rates of psychotropic medications in children and adolescents over
the 10-year period of the study. Significant increases were found among specific drug
classes as well. The largest increase in utilization rates across both HMO and Medicaid
populations was dextroamphetamine (Adderall). This medication is typically used for the
treatment of Attention-Deficity/Hyperactivity Disorder (ADHD), which accounted for a
7-fold increase among Medicaid populations and a 14-fold increase among the HMO
population. The second largest increase in utilization rates was for antidepressant

12

medications. A 10-fold increase was observed across Medicaid populations while a 5fold increase was observed across the HMO population.
Zito and colleagues (2003) hypothesized the dramatic increase in antidepressant
use among children and adolescents were due to the overall increase in use of selective
serotonin reuptake inhibitors (SSRIs) among adult populations. As prescriptions for
SSRIs increased in adult populations, physicians began prescribing these medications at
increasing rates to children and adolescents as well. Some classes of psychotropic
medications were used with significantly greater prevalence among Medicaid populations
than the HMO population. Neuroleptics, anticonvulsents used as mood stabilizers, and
lithium were utilized at a much greater rate among the Medicaid populations. These
medications are typically used to treat psychotic symptoms and to control violent
externalizing behaviors (Weller, Rowan, Elia, & Weller, 1999). Specifically, as a group,
these psychotropic medications were utilized at a rate in the Medicaid populations twice
as frequently as in the HMO population. Age specific patterns across both the Medicaid
populations and the HMO population were also investigated. The greatest changes for
Medicaid populations with respect to psychotropic medication utilization occurred in the
10 to 14 year old group in 1997. Specifically, this group had the greatest overall
utilization rate among all children and adolescents under 19 years of age. The
researchers hypothesized this may be in part due to the longer duration of this population
receiving stimulant medications and then receiving other psychotropic medications to
treat other symptoms (e.g., violent externalizing behaviors). The 5-9 year old group was
the previous Medicaid population with the highest utilization rate in 1987. With respect
to the HMO group, in 1997, 15-19 year olds had the highest utilization rate of
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psychotropic medications, replacing the 10-14 year old group which had the highest
utilization rate in 1987 (Zito et al., 2003).
With respect to gender, Zito and colleagues (2003) found males were prescribed
psychotropic medications at a rate twice that of females across the 10-year time period.
Additionally, they found the male to female utilization rates were greater in the Medicaid
populations than the HMO population. Boys were being prescribed antidepressants at a
significantly greater rate than the previous decade and utilization rates for stimulant
medications continued to be greater for boys than girls, although the disparity decreased
over the ten-year period. Dopamine agonists (mainly Clonidine) rose from near non-use
in the previous decade to marked increases across the time span of the study. Increased
utilization rates of neuroleptics and lithium were noted.
With respect to race, data were only available for individuals in the Medicaid
populations. Within this sample, there was no change in Caucasian and African
American utilization ratios over the 10-year period. Specifically, the disparity between
the two groups remained stable, particularly with respect to the use of antidepressants
being utilized by the Caucasian sample at a far greater extent. Overall disparities in
prescription of psychotropic medications related to race and other characteristics were
consistent with data from the National Ambulatory Medical Care Study (NAMCS) which
will be described below in detail (Goodwin, Gould, Blanco, & Olfson, 2001).
Goodwin et al. (2001) examined data from a nationally representative study
(NAMCS) of 166,256 office visits to physicians (i.e., pediatricians, psychiatrists, child
and adolescent psychiatrists, and general practitioners) for children and adolescents 19
years old and under. The researchers examined utilization rates of psychotropic
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medications. The results indicated psychotropic medications were prescribed to children
and adolescents 19 years of age and younger 2.2% of the total office visits. For office
visits in which a psychotropic medication was prescribed, stimulant medications were the
most frequent (54%) while antidepressants were second most frequently prescribed
followed by (30%); anxiolytics (7.2%); antipsychotics (including anticonvulsants; 7.2%);
and mood stabilizers (12.7%). The significant majority of psychotropic medications were
prescribed by general practitioners (e.g., family physicians) and pediatricians (85.4%)
compared with specialists (e.g., child and adolescent psychiatrists).
Consistent with Zito et al. (2003), male children and adolescents were more likely
to be prescribed a psychotropic medication, particularly stimulants. With respect to race,
Caucasian children and adolescents were prescribed a psychotropic medication at a
greater rate than children and adolescents of other races with the exception of stimulants.
Additionally, significant differences were noted among payment source (i.e.,
HMO vs. Medicaid). Specifically, if a child or adolescent used Medicaid as their
insurance, they were more likely to be prescribed certain classes of psychotropic
medications such as antipsychotics, anxiolytics, and mood stabilizers. Several
hypotheses for this phenomenon were presented. Specifically, children and adolescents
who utilize Medicaid are likely to be from low socioeconomic status (SES) households.
Research has linked low SES with an increased risk for mental illness (Buck, 1997).
Frazier and colleagues (2011) examined the prevalence and correlates of
psychotropic medication use in adolescents with a diagnosis of autism spectrum disorder
(ASD) who also were diagnosed with Attention Deficit/Hyperactivity Disorder (ADHD)
as well as youth only diagnosed with ADHD or ASD. Data from the National
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Longitudinal Transition Study, a 10 year prospective study with data collected from 2000
to 2009, were examined. The study included a nationally representative sample (n =
11,000) of adolescents ages 13-17 who received special education services. Youth who
were diagnosed with both ASD and co-occurring ADHD had the highest (58%) rates of
psychotropic medication use while youth with only ADHD had a 49% usage rate. Youth
with only an ASD diagnosis had the lowest usage rate in the study of 34%. Strengths of
this study include the large nationally representative sample and the fact that data are
relatively current. Weaknesses in this study include the reliance on parent self-report
data and the restricted age range of participants. As such, this study does not offer data
relevant to children below the age of 13 years.
More recently, Pringle and colleagues (2012) examined data from the Survey of
Pathways to Diagnosis and Services which is a nationally representative survey of
school-aged children with special health care needs aged 6-17 who have been diagnosed
with autism spectrum disorder, intellectual disability, or a developmental delay. The
researchers re-contacted, via telephone, parents of children who participated in the
original Survey of Pathways to Diagnosis and Services study in 2009 which examined
factors related to how families access care, received a diagnosis, and the frequency and
types of treatments and interventions accessed for their children. Eighty-seven percent
of the participants in the original study agreed to participate in the follow-up phone
interview. Pringle et al. (2012) found over one-half of all school-aged children diagnosed
with autism spectrum disorders (ASD) are prescribed at least one psychotropic
medication and almost one-third of school aged children with ASD use stimulant
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medications. Additionally, one-quarter of children with ASD take anti-anxiety or mood
stabilizing medications and one-fifth are prescribed antidepressant medications.
The strengths of this study included how recently it was conducted, the large
nationally representative sample size from which the results were drawn and the
relatively high (87%) rate of families who agreed to be re-interviewed about what
medications their children are currently taking. Additionally, the study employed an age
range (6 to 17 years) of child participants that closely matches the school age population.
Other researchers have found large numbers of children receiving special
education services for emotional and behavior disorders are being prescribed
psychotropic medications. Mattison (1999) conducted a study in which three year usage
of psychotropic medications among elementary school students in the Midwestern U.S.
who were receiving special education services under the category of serious emotional
disturbance was investigated. A total of 89 students ages 7-18 years participated in this
study. Using parent report data, 39% of the total sample of 89 students were reported to
be taking a psychotropic medication at the beginning of the three-year data collection.
Specifically, 26% were being prescribed stimulant medication while the remaining
students were being administered antipsychotics, antidepressants, and the
antihypertensive medication Clonidine as an off-label medication. Additionally, the
researchers found 17% of students were being administered multiple medications. A
portion of the students in this study were administered various medications at different
points throughout the study. Specifically, 24% received a psychotropic medication
consistently across the entire three-year span of the study. This study is the only one of
its kind at the time of writing to specifically examine the prevalence of psychotropic
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medication usage in students receiving special education services under the diagnostic
label of serious emotional disturbance.
Overall, the studies presented relating to psychotropic utilization rates indicate
school-age children are prescribed psychotropic medications at a rate that has risen
dramatically over the past decade. While Zuvekas et al. (2006) found stimulant
medications remained relatively stable, other researchers examining a broader scope of
psychotropic medication utilization rates in children found significant increases in other
classes of psychotropics (e.g., antidepressants, neuroleptics, and lithium). Further,
children with co-morbid diagnoses were found to have the highest utilization rates
(Frazier et al., 2011). Children in emotional and behavior disorder special education
classes utilize psychotropic medications at significantly greater rates than the overall U.S.
population when comparing utilization rates across studies.
The aforementioned studies are limited by the lapse in time between data
collection and publication. Additionally, the study by Mattison (1999) used a small
sample size which limits generalization of the results to the entire U.S. population. This
was not a limitation in the other studies reviewed as the researchers utilized larger and
more representative samples. Overall, the studies yield important information on the
current utilization rates across the U.S. with respect to psychotropic medication use in
children and adolescents.
Risks of Psychotropic Medication Use in Children and Adolescents
With the reported increase in use of psychotropic medications, there is a related
concern as to the short-and long-term side effects of these medications on children and
adolescents. The amount of evidence on the short-and long-term effects of medications

18

to treat various childhood disorders has been lacking. This had lead to the FDA issuing
“black box” warnings on certain classes of medications used in children and adolescents
under 18 years of age warning of serious potential side effects (e.g., suicidal ideation;
Food and Drug Administration, 2005).
Bush (2006) articulates the real and potential risks of widespread off-label
prescribing of psychotropic medications to children. Off-label prescribing refers to the
use of medications outside of the Food and Drug Administration guidelines for use.
Specifically, a medication may be approved for use for a certain condition but is
prescribed off-label to treat another condition based upon a clinician’s judgment. For
example, Clonidine is an anti-hypertensive agent originally approved to treat high blood
pressure but is frequently prescribed to treat symptoms of ADHD in children. Bush
(2006) discusses the paucity of clinical trials involving children and the widespread offlabel prescribing of medications which have never been studied in children. Bush gives
several plausible hypotheses for the lack of clinical trials involving children.
Specifically, as pharmaceutical companies are for-profit businesses, clinical trials which
may not lead to significant future profits may be de-emphasized while other clinical trials
may be given priority (e.g., adult clinical trials). Children are typically prescribed
medications for shorter durations than adults leading to less of the medication being
needed and therefore, less profit.
Christensen, Helms, and Chesney (1999) discuss the concerns related to
extrapolating childrens’ doses of medications from recommended adult doses. These
authors present the problems with this practice as children and adolescents’ bodies are
different than adults and therefore may metabolize the medication in a different manner.
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Drug absorption, metabolism, and secretion are different in childrens’ maturing bodies
than in an adult. However, pediatricians and other specialists are left with using
professional judgment when prescribing an approved drug for unapproved purposes (offlabel use). Therefore, as children and adolescents are being prescribed psychotropic
medications for which no specific clinical trials demonstrating their efficacy for this age
group occurs widely, close monitoring of medication response is vital. Given the
widespread use of psychotropic medications in children and the paucity of clinical trials
with this population along with the significant differences in children and adolescents’
biological development, close monitoring of medication benefits and side effects is
needed. Additionally, considering researchers have found many of the reasons children
are prescribed a psychotropic medication is to treat a symptom of a disorder that
manifests itself in the school environment, monitoring in this setting is crucial (Connor &
Barkley, 2006; Mattison, 1999). The next section of this literature review will document
the most prevalent childhood mental and behavioral disorders, the most commonly
prescribed medications, and the potential side-effects of pharmacological treatments on
academic and social functioning.
Effects of Psychotropic Medications on Academic, Behavioral, and Social
Functioning
The most up-to-date comprehensive review of psychotropic medications and
effects on academic and social functioning was completed by the American
Psychological Association (APA) Working Group on Psychoactive Medications for
Children and Adolescents (2006). This report includes examinations of risk-benefit ratios
of pharmacological treatments for the most common childhood disorders treated with
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psychotropic medications. The APA Working Group report comprehensively reviewed
extant literature in selected peer-reviewed journals as well as Food and Drug
Administration (FDA) safety and efficacy data. Additionally, psychosocial,
psychotropic, and combined treatments (i.e., psychosocial and psychotropic treatments)
were reviewed for evidence of efficacy. The disorders relevant to this study due to their
prevalence in child and adolescent populations reviewed by the Working Group include:
(a) Attention-Deficit/Hyperactivity Disorder (ADHD); (b) Oppositional Defiant Disorder
(ODD); (c) Conduct Disorder; (CD); (d) Tourette and tic disorders; (e) Obsessive–
Compulsive Disorder (OCD); (f) anxiety disorders; (h) depressive disorders; (i) bipolar
disorder; (j) schizophrenia; and (k) autism spectrum disorder. The information gleaned
from the APA Working Group’s review of each aforementioned disorder will focus on
the effects on academic and social functioning for the purposes of this literature review.
Table 1. examines in detail both the beneficial and deleterious effects of psychotropic
medications on academic and social functioning. The purpose of providing this
information is to inform the reader of the prevalence of each aforementioned disorder, the
types of psychotropic medications commonly used to treat each disorder and the side
effects each medication may have in children and adolescents.
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Table 1
Psychotropic Medications by Disorder: Evidence of Efficacy and Side Effects
Disorder/
Prevalence Rates

Most Common Psychotropic
Medications Utilized to Treat
Disorder:

Evidence of Efficacy in Children
and Adolescents

Common Side Effects

Attention-Deficit/
Hyperactivity
Disorder (ADHD)

Stimulants:
Methlyphenidate, a central
nervous system stimulant
Nonstimulants:
Straterra
Amoxetine (norepinephrine
reuptake inhibitor)
Clonidine (antihypertensive)

Stimulant medications:
Well documented (e.g., MTA
Cooperative Group, 1999)

Stimulant Medication Side Effects:
Decreased appetite, nausea, chronic headaches sleep
difficulties, growth problems (Connor & Barkley,
2006) anxious behaviors,
Nonstimulant Side Effects:
Chronic stomachaches, appetite suppression, Food and
Drug Administration (FDA) “black box” warning of
suicidal ideation in children under 18 years of age
(U.S. FDA, 2005) Risk of liver toxicity for amoxetine
Positive Effects on School Performance (Academic
and Psychosocial Functioning):
 Increased attention to task with appropriate
doses
 Decreased impulsivity behaviors
Negative Effects on School Performance (Academic
and Psychosocial Functioning):
 Reduced academic engagement due to
medication side effects (e.g., headaches,
nausea, anxious symptoms)
 Behavioral variability related to short half-life
of medication
 Lethargy in the school setting associated with
insomnia from stimulant medications

Prevalence Rates in
Children: 5%

Nonstimulants:
Less evidence of efficacy
Polypharmacological Treatments:
Little empirical evidence of efficacy,
regularly used to counteract sideeffects (e.g., insomnia from
stimulants) and treat co-morbid
disorders (e.g., oppositional defiant
disorder)
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Oppositional
Defiant Disorder
(ODD)
Conduct Disorder
(CD)

Stimulants:
Methylphenidate

Stimulant medications:
Well documented

Nonstimulants:
Atomoxetine
Clonidine

Nonstimulants:
Less evidence of efficacy

Antipsychotic medications:
Halperidol, Risperidone

Antipsychotic medications:
Off-label use only

ODD Rates in
Children: 2-16%
CD Prevalence
Rates in Children:
1-10%

Lithium

Stimulant Medication Side Effects:
Decreased appetite, sleep difficulties, growth problems
(Connor & Barkley, 2006) anxious behaviors
Nonstimulant Side Effects:
Chronic stomachaches, appetite suppression, Food and
Drug Administration (FDA) “black box” warning of
suicidal ideation in children under 18 years of age
(U.S. FDA, 2005), drowsiness decreasing focus and
attention leading to reduced academic performance)
Antipsychotic Medication Side Effects:
Extrapyrimidal symptoms (permanent)
Headaches, drowsiness, nausea
Memory loss, decreased cognitive functioning
Motor tremors
Positive Effects on School Performance (Academic
and Psychosocial Functioning):
 Decreased externalizing symptoms
 Possibly may increase efficacy of behavioral
interventions
Negative Effects on School Performance (Academic
and Psychosocial Functioning):
 Reduced academic engagement due to
medication side effects (e.g., headaches,
nausea, anxious symptoms)
 Behavioral variability related to short half-life
of medication
 Lethargy in the school setting associated with
insomnia from stimulant medications
 Memory loss as a side effect of lithium,
cognition difficulties
 Decreased fine motor skills (resulting from
motor tremors)
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Tic Disorders
(Including
Tourettes
Syndrome)

Alpha 2 agonists
Clonidine
Guanfacine

Randomized clinical trial data
available, however extremely small
sample sizes were employed

Prevalence Rates in
Children and
Adolescents: 2%

Typical
Neuroleptics/Antipsychotics
Halperidol
Pimozide

Long-term effects unknown on all
classes of medication in children and
adolescents

Atypical Neuroleptics
Risperidone
Ziprazidone
Atmoxetine

Alpha 2 agonists
Sedation, dry mouth, headaches, irritability, dysphoria,
postural hypotension, Guanfacine is associated with
less risk of sedation

Typical Neuroleptics
Sedation, cognitive dulling, akathisia, extrapyrimidal
symptoms (EPS), risk of tardive dyskinesia, dysphoria
Atypical Neuroleptics
Sedation, weight gain, EPS, galactorrhea, dysphoria,
increased risk of hepatoxicity, diabetes mellitus
Positive Effects on School Performance (Academic
and Psychosocial Functioning):
 Decreased externalizing symptoms
 Increases social/emotional functioning by
decreasing symptoms
 Possibly may increase efficacy of
psychosocial interventions
Negative Effects on School Performance (Academic
and Psychosocial Functioning):
 Loss of academic skills due to medication side
effects (e.g., cognitive dulling)
 Reduced academic engagement due to
medication side effects (e.g., sedation,
headaches, dysphoria, cognitive dulling,
lethargy)
 Decreased fine motor skills (resulting from
motor tremors)
 Increased risk of suicidal ideation resulting in
decreased school functioning (both academic
engagement and social functioning) associated
with atmoxetine
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Obsessive
Compulsive
Disorder (OCD)

Prevalence Rates in
Children and
Adolescents: 0.52.0%

Selective Seratonin Reuptake
Inhibitors (SSRIs)
Prozac
Paxil
Zoloft
Celexa

Some evidence of efficacy, small
sample sizes
Long-term effects unknown

SSRIs
Nausea, disinhibition, loss of appetite or weight gain,
sedation, tremors, potential suicidal ideation (FDA
warning)
*Must be closely monitored to ensure child or
adolescent is regularly taking medication, otherwise
serious withdrawal symptoms can occur

Clomipramine
Clomipramine
Potential cardiotoxicity in children and adolescents
(used very infrequently), sedation, fainting, seizures,
tremors, weight gain
Positive Effects on School Performance (Academic
and Psychosocial Functioning):
 Decreased symptoms of disorder
 Increases social/emotional functioning by
decreasing symptoms
 Possibly may increase efficacy of
psychosocial interventions
Negative Effects on School Performance (Academic
and Psychosocial Functioning):
 Reduced academic engagement due to
medication side effects (e.g., headaches,
nausea, sedation)
 Disinhibition associated with impulsive
behaviors
 Psychosocial difficulties associated with
weight gain among peers
 Increased risk of suicidal ideation resulting in
decreased school functioning (both academic
engagement and social functioning)
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Disorder/
Prevalence Rates

Most Common Psychotropic
Medications Utilized to Treat
Disorder:

Evidence of Efficacy in Children
and Adolescents

Common Side Effects

Anxiety Disorders
(Generalized
anxiety disorders,
social anxiety
disorders,
separation anxiety
disorders)

Selective Seratonin Reuptake
Inhibitors (SSRIs)
Prozac
Paxil
Zoloft
Celexa

Some evidence of efficacy, small
sample sizes

SSRIs
Nausea, disinhibition, loss of appetite or weight gain,
sedation, tremors, potential suicidal ideation (FDA
warning)
*Must be closely monitored to ensure child or
adolescent is regularly taking medication, otherwise
serious withdrawal symptoms can occur

Prevalence Rates in
Children and
Adolescents: 1220%

Long-term effects unknown

Benzodiazapines
Found to be ineffective for
children, rarely used in
adolescents due to habitforming dangers

Positive Effects on School Performance (Academic
and Psychosocial Functioning):
 Decrease of negative symptoms of disorder
 Increase social interaction
 Possibly increase effects of psychosocial
interventions
Negative Effects on School Performance (Academic
and Psychosocial Functioning):
 Reduced academic engagement due to
medication side effects (e.g., headaches,
nausea, sedation)
 Disinhibition associated with impulsive
behaviors
 Psychosocial difficulties associated with
weight gain among peers
 Increased risk of suicidal ideation resulting in
decreased school functioning (both academic
engagement and social functioning)
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Depressive
Disorders
Prevalence Rates in
Children and
Adolescents: Up to
20% at some point
during childhood
through
adolescence

Selective Seratonin Reuptake
Inhibitors (SSRIs)
Prozac
Paxil
Zoloft
Celexa

Some evidence of efficacy, small
sample sizes, more efficacy in
adolescent populations
Long-term effects unknown

SSRIs
Nausea, disinhibition, loss of appetite or weight gain,
sedation, tremors, potential suicidal ideation (FDA
warning)
*Must be closely monitored to ensure child or
adolescent is regularly taking medication, otherwise
serious withdrawal symptoms can occur

Tricyclics
No efficacy data in school-age
populations

Bipolar Disorder

Lithium

Prevalence Rates in
Children and
Adolescents: 1%

Valporate
Risperidone

Paucity or randomized controlled
trials, National Institutes of Mental
Health is sponsoring medium-size
study comparing efficacy of lithium,
valporate, and risperidone in children
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Tricyclics
Nausea, cognitive retention difficulties, enuresis
(daytime and night) blurred vision
Positive Effects on School Performance (Academic
and Psychosocial Functioning):
 Decrease of negative symptoms of disorder
 Increase social interaction
 Possibly increase effects of psychosocial
interventions
Negative Effects on School Performance (Academic
and Psychosocial Functioning):
 Reduced academic engagement due to
medication side effects (e.g., headaches,
nausea, sedation)
 Disinhibition associated with impulsive
behaviors
 Psychosocial difficulties associated with
weight gain among peers
 Increased risk of suicidal ideation resulting in
decreased school functioning (both academic
engagement and social functioning)

Lithium
Difficulty with memory (e.g., word retrieval) working
memory deficits, cognitive dulling, weight gain,
increased risk for Type II diabetes, lipid level
elevation, transaminase elevation

ages 8-14 with bipolar disorder

Long-term effects unknown

Valporate
Change in appetite; constipation; diarrhea; dizziness;
drowsiness; hair loss; headache; indigestion; nausea;
stomach pain; trouble sleeping; vomiting; weight
changes
Risperidone
Extrapyramidal effects (sudden, often jerky,
involuntary motions of the head, neck, arms, body, or
eyes), dizziness, hyperactivity, tiredness, abdominal
pain, fatigue, fever and nausea. Orthostatic
hypotension during the early phase of treatment (drop
in their blood pressure when rising from a lying
position and may become dizzy or even lose
consciousness)
Positive Effects on School Performance (Academic
and Psychosocial Functioning):
 Decrease or elimination of negative
symptoms of disorder
 Increase social interaction
Negative Effects on School Performance (Academic
and Psychosocial Functioning):
 Reduced academic engagement due to
medication side effects (e.g., headaches,
nausea, sedation)
 Disinhibition associated with impulsive
behaviors
 Psychosocial difficulties associated with
weight gain among peers
 Increased risk of suicidal ideation resulting in
decreased school functioning (both academic
engagement and social functioning)
 Memory loss as a side effect of lithium,
cognition difficulties
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Childhood-Onset
Schizophrenia
Prevalence Rates in
Children and
Adolescents: 0.5%
(1% onset before
age nine, 9% before
age 15)

Typical
Neuroleptics/Antipsychotics
Halperidol
Pimozide
Risperidone
Olanzapine

Paucity of data in pediatric
populations
Long-term effects unknown

Typical Neuroleptics
Extrapyramidal effects (sudden, often jerky,
involuntary motions of the head, neck, arms, body, or
eyes), dizziness, hyperactivity, tiredness, abdominal
pain, fatigue, fever and nausea. Orthostatic
hypotension during the early phase of treatment (drop
in their blood pressure when rising from a lying
position and may become dizzy or even lose
consciousness)
Type II diabetes, difficulty with word retrieval,
working memory deficits, cognitive dulling
Positive Effects on School Performance (Academic
and Psychosocial Functioning):
 Decrease or elimination of negative
symptoms of disorder
 Increase social interaction
Negative Effects on School Performance (Academic
and Psychosocial Functioning):
 Reduced academic engagement due to
medication side effects (e.g., headaches,
nausea, sedation)
 Disinhibition associated with impulsive
behaviors
 Psychosocial difficulties associated with
weight gain among peers
 Increased risk of suicidal ideation resulting in
decreased school functioning (both academic
engagement and social functioning)
 Memory loss as a side effect of lithium,
cognition difficulties
 Effects of orthostatic hypotension (may cause
dizziness, loss of consciousness) in early
phases of treatment

29

Disorder/
Prevalence Rates

Most Common Psychotropic
Medications Utilized to Treat
Disorder:

Evidence of Efficacy in Children
and Adolescents

Common Side Effects

Autism Spectrum
Disorder (ASD)

33-47% of children with ASD
are prescribed a psychotropic
medication*
SSRIs
Prozac
Paxil
Zoloft
Celexa
Alpha 2 agonists
Clonidine
Guanfacine
Atypical Neuroleptics
Risperidone
Ziprazidone
Amoxetine
Stimulants:
Methlyphenidate, a central
nervous system stimulant

Limited randomized controlled
trials utilizing small sample sizes

SSRIs
Nausea, disinhibition, loss of appetite or weight gain,
sedation, tremors, potential suicidal ideation (FDA
warning)
*Must be closely monitored to ensure child or
adolescent is regularly taking medication, otherwise
serious withdrawal symptoms can occur

Prevalence Rates in
Children and
Adolescents: 1 in
150 children and
adolescents

Alpha 2 agonists
Sedation, dry mouth, headaches, irritability, dysphoria,
postural hypotension, Guanfacine is associated with
less risk of sedation

Atypical Neuroleptics
Sedation, weight gain, EPS, galactorrhea, dysphoria,
increased risk of hepatoxicity, diabetes mellitus

Less Common:
Lithium
Divalproex Sodium

Stimulant Medication Side Effects:
Decreased appetite, chronic headaches sleep
difficulties, growth problems (Connor & Barkley,
2006) anxious behaviors
Lithium
Difficulty with memory (e.g., word retrieval) working
memory deficits, cognitive dulling, weight gain,
increased risk for Type II diabetes, lipid level
elevation, transaminase elevation
Positive Effects on School Performance (Academic
and Psychosocial Functioning):
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Decreased externalizing symptoms
Increases social/emotional functioning by
decreasing symptoms
 Possibly may increase efficacy of
psychosocial interventions
Negative Effects on School Performance (Academic
and Psychosocial Functioning):
 Reduced academic engagement due to
medication side effects (e.g., headaches,
nausea, sedation)
 Disinhibition associated with impulsive
behaviors
 Psychosocial difficulties associated with
weight gain among peers
 Lethargy in the school setting associated with
insomnia from stimulant medications
 Increased risk of suicidal ideation resulting in
decreased school functioning (both academic
engagement and social functioning)
 Memory loss as a side effect of lithium,
cognition difficulties
 Effects of orthostatic hypotension (may cause
dizziness, loss of consciousness) in early
phases of treatment
Adapted from: APA Working Group on Psychoactive Medications for Children and Adolescents, (2006)
*(Aman, Lam, & Collier-Crespin, 2003; Aman, Lam, & Van Bourgondien, 2005; Witwer & Lecavalier, 2006).
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Taken together, the prevalence rates and variety of medications prescribed to
school-aged children has increased substantially over the past decade. While the use of
psychotropic medications in school-aged populations has resulted in positive treatment
gains for many, there is a paucity of evidence on the effects, particularly long-term
effects of such pharmacological treatments on children. Randomized studies are
currently being conducted to evaluate short and long-term effects of pharmacological
treatment. However, many children and adolescents have already or currently are
prescribed medications for which there is little to no scientific evidence of their effects.
The effects on school performance are even less studied, even as public school personnel
are asked to play a larger role in the treatment of children with mental health and
behavioral disorders.
Legal and Ethical Issues in Medication Utilization in Public Schools
Researchers report that public school personnel are playing an ever increasing
role in pharmacological treatment of school-aged children. Specifically, school personnel
are increasingly being asked to dispense medications including controlled medications to
students during the school day. DuPaul and Carlson (2005) discuss the emerging trend of
non-medical school personnel (e.g., secretaries and instructional assistants) being asked
to dispense psychotropic medications including controlled medications with little or no
supervision. School nursing services are limited in many school systems, particularly in
rural areas. As a result, other non-medical school personnel are asked to perform these
functions which increases the probability of medication administration errors (e.g., lack
of follow-up to ensure child took his or her medication, overdosing, giving stimulants
away to other students; DuPaul et al., 2005).
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The involvement of school personnel in the utilization and administration of
psychotropic medications is controversial. For example, school personnel are frequently
the first to recommend treatment including pharmacological agents to treat the symptoms
of ADHD even before a formal medical diagnosis (dosReis, 2003). While school
personnel can play a pivotal role in monitoring treatment efficacy as well as side effects
(DuPaul & Carlson, 2005), both at the federal and state level, legislation has been enacted
to limit the role of school personnel involvement in the recommendation or requirement
that a child take a psychotropic medication as a condition of participation in any school
activity (academic, athletic, or social). Specifically, the reauthorization of IDEA (2004)
includes provisions for each state to develop policies and practices prohibiting public
school personnel from recommending parents seek prescriptions for controlled
substances such as stimulants as a condition for their children to attend school.
Additionally, the Child Medication Safety Act requires states receiving federal education
funds to develop specific policies and procedures related to prohibiting school districts
from requiring a child take a psychotropic medication as a condition of attending school.
As a result, 23 states have enacted legislation prohibiting school employees from
recommending psychotropic medication to parents to treat any disorder. This includes
the State of Florida (National Conference of State Legislatures, 2004). In the State of
Florida Senate Bill 1090, signed into law in 2005, prohibits school personnel (including
school psychologists) from coercing parents to have their child prescribed a psychotropic
medication. In addition, the Bill creates safeguards giving parents the right to refuse a
request by school personnel to conduct a psychological evaluation on their child. The bill
also clarifies school personnel’s ability to share information related to emotional and
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behavioral functioning with parents to allow for information sharing but specifically
excludes any coercive practices related to pressuring parents to obtain psychotropic
medications for their child as a condition of attending school (National Conference of
State Legislatures, 2004).
While this is obviously a well-intentioned mandate, it also can have negative
collateral consequences. For instance, some of the most efficacious treatments for certain
disorders (e.g., ADHD) include the use of stimulant medications which fall into the
category of psychotropic medications. A school psychologist who is well-grounded in
advocating evidence-based treatments may feel prohibited from recommending that
parents speak to their physician about an evidence-based treatment for their child out of
fear of liability.
As previously discussed, this can have negative consequences for certain school
employees who are typically charged with evaluating and making recommendations that
are based on scientific research (e.g., school psychologists). Given this legislation and
constraints on school employees (including school psychologists), the next section will
examine the extant research on medication monitoring practices in public schools.
Medication Monitoring Practices in Public Schools
Guerasko-Moore, DuPaul, and Power (2005) conducted a survey that examined
medication monitoring practices of school psychologists related to the treatment of
ADHD. The survey assessed four areas related to medication monitoring by school
psychologists specific to children with ADHD. The areas assessed included (a) the self
reported use of procedures for monitoring the effects of medications on the symptoms of
ADHD; (b) training related to medication monitoring; (c) perceptions of effectiveness,
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acceptance, and feasibility of medication monitoring practices; and (d) perceptions of
barriers and facilitators related to medication monitoring by school psychologists. The
researchers obtained a survey return rate of 64.7% with a total of 437 surveys included in
analyses. The demographic data obtained through this survey were aligned with NASP
membership demographics for the year of the study with respect to age, gender, and
ethnicity.
Guerasko-Moore et al. (2005) found that 54.5% of survey participants reported
they engaged in medication monitoring as part of their work as a school psychologist.
Additionally, survey participants who engaged in medication monitoring reported
monitoring an average of 1-5 students diagnosed with ADHD per year. Survey
participants also indicated a relatively strong agreement (3.84 out of 5 on a Likert scale)
with the statement “monitoring the effects of medication for students with ADHD is a
role school psychologists should play.” These findings indicate that while medication
monitoring is a role that may not be officially required in many school psychologists’ job
duties, it is one many reported perceiving as important and necessary. With respect to
actual practices, the majority of school psychologists who reported engaging in
medication monitoring for students with ADHD used teacher rating forms, direct
behavioral observations, and teacher interviews.
Perceptions of effectiveness, acceptance, and feasibility of medication monitoring
practices in addition to actual practices were also assessed. Guerasko-Moore et al. (2005)
found direct observation, teacher rating forms, and teacher interview were rated as the
most effective, feasible, and had the highest acceptance for monitoring medications of
students with ADHD. Less effective, feasible, and acceptable practices were parent
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rating forms, parent interview, student interviews, student grades, student self-report
rating, and curriculum based measurement and assessment practices (CBM/CBA).
Previous research has found one of the lowest rated methods in the current study,
CBM/CBA, has significant efficacy when utilized properly (Stoner, Carey, Ikeda, &
Shinn, 1994).
Training in medication monitoring was also assessed in this study. In line with
other studies (i.e., Carlson & Demaray, 2001) Gureasko-Moore et al. (2005) found fewer
individuals indicated they received formal training in medication monitoring (42% of
study participants) than those who indicated they did not receive formal training (58%).
The most common methods for training were graduate coursework (14.3%) and
professional workshops (18.1%). Examining the differences between the amount of time
spent engaged in medication monitoring activities and trained versus untrained school
psychologists, those with training in medication monitoring reported significantly more
time engaging in this practice for students with ADHD.
Perceptions of barriers and facilitators related to medication monitoring by school
psychologists were rated on a Likert scale ranging from one (significant barrier) to five
(significant facilitator) in engaging in medication monitoring. The researchers found
time was the most significant barrier with accessibility and perceptions of school
psychologists’ role in medication monitoring by physicians being less significant barriers.
In terms of facilitators, the highest rating was teacher support while administrative
support and amount of training were perceived to be the weakest facilitators related to
medication monitoring.
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The results of this study indicate the majority of school psychologists believe
medication monitoring is an appropriate professional role. Over half of all respondents
indicated they are currently involved in medication monitoring for students with ADHD
to some degree. The representative sample from which this study was drawn, as well as
the relatively high return rate, enhances the generalizability of the results of this study to
school psychologists who are members of the National Association of School
Psychologists (NASP).
This study has several limitations. Specifically, this study employed self-report
data that are not cross referenced. The results of this study cannot take into account the
misreading of a question or misrepresentation of answers as the survey was anonymous.
Also, this study utilized only the NASP database. While the NASP database allows for
random selection of a representative sample of NASP members, it does not encompass all
school psychologists currently working in the U.S. Additionally, the researchers noted
that not all NASP members update their demographic information to indicate if they
work in a school or another setting and may have filled out the survey regardless. This
study also found some level of discrepancy between overall NASP demographics and
study demographics related to training and years of experience. Lastly, this study
examined medication monitoring limited to students taking medication for ADHD. As
this literature review delineates, a multitude of medications are being taken by children
with ADHD and a number of other disorders.
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Collaboration between School Personnel and Medical Providers
Extant research on collaboration between pediatricians and school personnel
indicates overall, pediatricians would like more information regarding medication effects
from school personnel. Haile-Mariam , Bradley, and Johnson (2002) conducted a survey
of pediatricians assessing the type and format of information needed from schools to
assist in the treatment of ADHD. The researchers obtained a 66% return rate totaling 332
returned surveys. Forty five percent of the respondents worked in a group medical
practice and 59% were in practice over 15 years. Information related to medication
monitoring gleaned from this study indicates pediatricians want more information from
school personnel. Specifically, regarding information related to medication monitoring
and treatment effects, 81% of pediatricians indicated they wanted information from
school personnel such as direct observation of student behavior. Additionally, 45% of
surveyed pediatricians indicated they would like information on medication side effects.
Only 9% of pediatricians reported school personnel providing this information.
Collaboration between school personnel and medical providers is the first step in
effective medication monitoring (Wodrich et al., 1999). Collaboration between medical
providers and school personnel enhances the level and continuity of care for children.
Researchers have identified the school psychologist as a professional uniquely suited for
collaboration with medical providers such as physicians to enhance the outcomes for
children prescribed psychotropic medications (Power et al., 1995; Power, DuPaul,
Shapiro & Parrish, 1998; Wodrich et al., 1999). The next section of this literature review
will discuss the unique skills of the school psychologist and how they relate to
medication monitoring.
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Role of the School Psychologist
Several researchers have advocated for school psychologists’ involvement in the
ever increasing numbers of children being prescribed psychotropic medications who are
also attending school. Specifically, DuPaul and Carlson (2005) advocated for increased
school psychologist involvement in helping physicians and families make more effective
decisions regarding the dosage, clinical effects, and side effects of various psychotropic
medications. School psychologists’ are in a unique and well-suited position to assist in
medication monitoring considering the following skills many school psychologists
possesses: (a) training in data-based decision making; (b) training in systematic problemsolving examining all factors from an ecological perspective such as the environment,
specifically the child, the curriculum, and family influences; (c) ability to progress
monitor using methods sensitive to small changes in performance; and (d) the ability to
observe children and adolescents in the school environment which typically is
significantly different from office-based settings or other community settings (DuPaul &
Carlson, 2005). The aforementioned skills school psychologists’ possess enable them to
engage in medication monitoring as well as collaboration with the prescribing physician
and the school nurse who may have responsibility to oversee administration of
medications. Collaboration between the school nurse and school psychologist can
harness both professional’s knowledge and skills. The school nurse is trained in
administration of medication, common side effects, and adverse reactions while the
school psychologist brings knowledge of assessment of behavior (the variable medication
is most often used to affect) as well as collaboration skills to bring together multiple
professionals from different disciplines.
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School psychologists possess numerous strengths related to medication
monitoring. Specifically, school psychologists are in a unique position to evaluate the
medication effects within the natural environment (i.e., school environment). School
psychologists have specific training utilizing broad and narrow band rating scales, direct
observation of behavior using narrative recording methods as well as standardized
behavior rating methods. For example, the Behavior Observation System in Schools
(BOSS; Shapiro, 2010) has been found to be efficacious to evaluate medication efficacy
(Power, DuPaul, Shapiro, & Kazak, 2003). Also, review of permanent products such as
the accuracy and completion of assignments are available to school psychologists and
have been shown to be sensitive to medication effects (Power et al., 2003). Additionally,
the use of curriculum based measurement (CBM) has been shown to be an efficacious
method of determining the response-to-medication for certain disorders such as ADHD
(Stoner, Carey, Ikeda, & Shinn, 1994). CBM has been found to be sensitive to changes
in dosages of methylphenidate to treat symptoms of ADHD (Stoner et al., 1994). School
psychologists may also assist in determining optimal dosage (DuPaul & Carlson, 2005).
Psychotropic medications interact differently with each child and dose-response effects
can vary widely for children. As a result, determining optimal dosages is essential to
obtain the greatest medication efficacy (DuPaul et al., 2005). School psychologists are in
the unique position to utilize the aforementioned techniques (e.g., CBM and direct
behavior observations in the school environment) to assist in finding an optimal
medication dosage for a child.
The school psychologist can assist in designing and implementing a medication
trial in collaboration with the child’s physician (DuPaul & Carlson, 2005). A medication

40

trial will be a temporary trial of a pre-specified dose of a psychotropic medication which
may or may not be known to those evaluating its effects. An open trial is one where all
parties know the dosage and type of medication. Blinded trials call for only certain
individuals (not involved in evaluating the medication’s efficacy) to know the dosage and
type. The overall goal is to identify the most appropriate dosage with the least side
effects and maximum benefit for the child. Collaboration between the school
psychologist and other school personnel such as the school nurse with the child’s
physician is an important aspect of a well designed medication trial (DuPaul & Carlson).
Children currently receiving a psychotropic medication may need continual
progress monitoring to best assess overall efficacy (DuPaul & Carlson, 2005). Progress
monitoring in the school environment can prove valuable to a treatment team as seeing a
child in an office setting may be not indicative of actual functioning within the school
environment (Pelham et al., 2000). The level of behaviors occurring in the natural setting
can provide valuable information to the treatment team, particularly when the information
is provided by an individual with specific training in assessing and observing behavior
such as the school psychologist (DuPaul et al., 2005).
Finding an optimal dosage (least side effects and maximum beneficial effects) for
children receiving a psychotropic medication is critical to balance to cost and risks of the
medication (e.g., side effects) to the benefits (e.g., improved functioning). For example,
children with ADHD may react differently to the same medication and dose even when
considering gender, age, and height (DuPaul et al., 2005). The MTA Cooperative Group
(1999) which conducted the most comprehensive evaluation of effects of treatments for
ADHD to-date, found for children with ADHD, dose-response varied considerably across
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children. This was found while holding constant other factors such as gender, age, and
weight. The results of a follow-up study by the MTA Cooperative Group (2009)
recommend a highly individualized medication monitoring plan due to wide ranging
dose-responses among children (Molina, et al., 2009).
DuPaul et al. (2005) discussed possible ways for school psychologists to assist in
determining optimal dosage. Specifically, the treatment team comprised of the physician,
parent, teacher, and school psychologist determine keystone behaviors which will serve
as outcome data. Keystone behaviors are behaviors which if affected will also have
collateral effects on other areas of functioning. For example, the researchers list possible
keystone behaviors such as accuracy of completed assignments along with reductions in
disruptive behavior in the classroom. After the team has agreed upon keystone behaviors
to monitor, the school psychologist can assist in collecting assessment data to help
determine the lowest efficacious dosage.
Wodrich and Landau (1999) also advocate for an increased role of the school
psychologist in collaboration between medical and school entities including monitoring
of medications. Specifically, the authors state that school psychologists are in a unique
position to assist in contributing to effective outcomes for children with medical
conditions who may be prescribed a psychotropic medication. Wodrich et al. (1999)
recommend strategic partnerships between school psychologists and local pediatricians
for a variety of reasons. One of the most compelling reasons the authors cite is the school
psychologist’s access to children in the natural environment. DuPaul et al. (2005) also
state access to the natural environment as well as school psychologists’ possessing the
requisite knowledge and skills to effectively monitor medications make this school
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professional uniquely suited for this practice. Wodrich et al. (1999) recommend building
a working relationship between primary care pediatrics and school psychologists,
particularly for children with involved medical concerns. The authors also recommend
school psychologists and pediatricians forge working alliances for school-age children
taking medications that may impact academic as well as social-emotional functioning.
Sulkowski, Jordan, and Nguyen (2009) also advocate for increasing collaboration
between physicians prescribing psychotropic medications and school psychologists. The
authors present numerous strategies aimed at decreasing barriers and increasing
opportunities for collaboration. Specifically, Sulkowski et al. describe using guidelines
set for by the American Academy of Child and Adolescent Psychiatry (2004) to support
collaborative efforts and avoid role confusion. The authors advocate for school
psychologists to assist the prescribing physician in better understanding school systems
and becoming more informed about the school environment and specific adaptations that
can be made (e.g., lower task demands, assign a peer helper). Also, the authors advocate
for school psychologists taking leadership roles in their school systems by creating
district-wide consultation roles with local pediatricians and other physicians (e.g., child
and adolescent psychiatrists). Additionally, Sulkowski et al. advocate forging alliances
with physicians to promote district-wide services such as providing pharmacological
consultations and in-service trainings on psychotropic medication management. By
utilizing a district-wide approach, resources of the consulting physician and the school
psychologist can be more efficiently utilized.
Given these recommendations on forging collaborative partnerships, research has
found physicians are open and willing to collaborate with school personnel; particularly
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school psychologists on issues related to medications children are receiving (Ax,
Bradley-Klug, & Scott, 2003; Barnett, Duncan, & O’Connors, 1999). However, in
general, physicians were unsure of how to collaborate (e.g., who to contact within the
school system; Ax et al., 2003). Other researchers have found physicians attempted to
collaborate first with the school nurse and classroom teacher while 40% reported
attempting to collaborate with the school psychologist (Bradley-Klug, Sundman, Nadeau,
Cunningham, & Ogg, 2010). The extant research on this topic is limited by only the
aforementioned studies as well as small to medium sample sizes reported. Therefore, the
information gleaned from each study cannot be generalized across all physicians.
Although medication monitoring is a practice school psychologists may be
equipped to assist in and medical providers indicate they would like this information,
there are ethical considerations that must be taken into account. Specifically, legislation
previously mentioned may prohibit a school psychologist from recommending an
efficacious treatment for a child because that treatment may involve the use of a
psychotropic medication. For example, Carlson, Thaler, and Hirsch (2005) discuss an
example where a research-supported efficacious treatment for ADHD involves a multimodal approach that can include the use of a stimulant medication which falls under the
class of psychotropic medications. A school psychologist may feel hesitant to discuss
with parents all approaches due to fear of liability or noncompliance with educational
law. Carlson and colleagues (2005) propose ethical considerations school psychologists
should take into consideration when engaging in medication monitoring. Carlson and
colleagues advocate utilization of a problem-solving model to take into consideration all
variables and possible outcomes as an important step for school psychologists who
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engage in medication monitoring. A problem-solving approach leads to a balance
between acting in the best interests of the child, utilizing evidence-based treatment
approaches, and following district/state policies related to medications.
Research examining school psychologists’ knowledge and training related to
psychopharmacology and medication monitoring is lacking. However, research indicates
school psychologists are routinely involved in consultation (e.g., member of school-based
problem-solving team, involved in evaluations for special education services) where
medications are being utilized. School psychologists may also be suited to collaborate
with the child, his or her parents, and the prescribing physician to implement a behavioral
plan to increase adherence to medication regimens if this is a problem for a child or
adolescent. Research has found adherence to medication regimens occurs due to a
myriad of factors such as intolerable side effects and misunderstanding of the need to
regularly take medication (Bussing, Koro-Ljungberg, & Gary, 2005; Gau, Chen, &
Chow, 2008).
Carlson, Demaray, and Hunter-Oehmke (2006) conducted a survey examining
school psychologists caseloads in which students were receiving medications, types of
training related to pharmacology, and consultative efforts monitoring medications. A
national sample of 320 school psychologists who were members of NASP was utilized in
the analyses. A 37% return rate was reported. Demographic data obtained in the survey
indicated the sample was consistent with NASP membership with respect to gender,
ethnicity, type of degree, and years of experience. The findings indicated 63% of school
psychologists were involved in medication evaluation trials in the past year. Also, in
nearly a quarter of cases school psychologists were involved, the children were receiving
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psychotropic medication as part of an intervention. Additional findings included the
majority of school psychologists have not had formal university training in child
psychopharmacology (81%) and the primary method school psychologists acquired
background knowledge in child psychopharmacology was through professional
workshops (88%), and independent reading (96%). The depth and comprehensiveness of
the workshop training was not delineated in the survey. Approximately 62% of school
psychologists reported working with physicians and parents to evaluate medication trials
for children, but collaborative monitoring was infrequent. Additionally, these instances
were limited to treatment of ADHD.
The strengths of this study include being the only known survey to assess
medication monitoring and child psychopharmacology among school psychologists. The
researchers highlighted important information, particularly with respect to the number of
cases on which school psychologists are consulting that include medication monitoring.
Limitations of this study include a relatively small return rate (34%), potentially
lessening the degree to which one can make confident conclusions about the overall
prevalence of medication monitoring practices and overall conclusions based on the
survey. Additionally, while simple and straightforward to read, the survey could have
gleaned more information from respondents that would be valuable. For instance, 63%
of respondents indicated they collaborate with physicians, but no information was
provided about what practices were used when evaluating pharmacological interventions.
Nevertheless, this survey is the only examination of both school psychologists’
knowledge and training in child psychopharmacology and medication monitoring
practices.

46

Conclusions
Current research indicates the utilization rates of psychotropic medications
prescribed to school-age children has remained relatively stable to treat some disorders
(i.e., ADHD) while the utilization rates of psychotropic medications used to treat other
disorders (e.g., depression, autism, Aspergers syndrome, and ODD/CD) have increased
dramatically over the past decade (Abrams, Flood, & Phelps, 2006). Many of the current
psychotropic medications being used in pediatric populations have no randomized
controlled trials demonstrating their efficacy in this population. As a result, the vast
majority of psychotropic medications are approved for use in adults but are prescribed
off-label to children. Thus in many cases, the side-effects and long-term effects on
academic and social-emotional functioning in children have not been studied and can
vary dramatically between children due to different rates medications are metabolized.
Many of the medications being utilized in pediatric populations have both positive and
negative possible effects on school performance. Some effects are directly linked to
academic performance (e.g., memory loss, cognitive dulling) which may go unnoticed by
other school personnel without training in assessment and progress monitoring.
Children spend a majority of their waking hours in the school environment. The
psychotropic medications are in many cases prescribed to treat problem behaviors that are
occurring in the school environment as school personnel has been found to be one of the
first to suggest the need for medication dosReis et al. (2003). School psychologists are in
a unique position to assist in medication monitoring due to specialized training in
progress monitoring, assessment of behavior, collaboration and consultation skills, and
training in systematic problem-solving.
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There are significant gaps in the literature regarding the practices and prevalence
of medication monitoring beyond students taking medication for ADHD. Additionally,
no research to date has examined the acceptability and feasibility of monitoring
medications beyond those for ADHD. Prevalence rates suggest significant amounts of
children and adolescents may be coming to school taking psychotropic medications for
other disorders (e.g., challenging behavior, anxiety and/or depressive symptoms).
Additionally, research has not yet examined the degree to which school personnel are
informed about a child who is taking a psychotropic medication so that an individual can
assist in monitoring its effects in the school environment. Given the variety of
psychotropic medications children are currently receiving, the lack of efficacy studies of
the use of psychotropic medications in children examining short-term and long-term
effects, potential serious side-effects (e.g., suicidal ideation) more research is needed.
This is particularly important as more children and adolescents are prescribed
psychotropic medications for which a paucity of efficacy research is available. Side
effects, interaction effects from multiple medications being utilized (polypharmacy) can
cause acute reactions that may at best impede academic performance and at worst cause
serious side effects (e.g., extra pyramidal symptoms, suicidal behavior). The current
study addresses these gaps in the literature.
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Chapter Three
Method
Introduction
This chapter describes the methods used to collect data for the study. The
following facets of the study will be described in this order: (a) participants; (b)
respondent information, (c) demographic information; (d) materials used in the study, and
(e) procedures.
Participants
Participants for this study consisted of a sample of practicing school psychologists
from the 2010-2011 Florida Association of School Psychologists (FASP) membership
directory. Currently, there are approximately 500 members listed as active in the
directory. School psychologists who are not currently working in public schools or who
are not currently working in a practitioner capacity (e.g., retired or not working in a
school setting) were removed from the sample resulting in a total sample of 273 potential
respondents.
Survey studies have examined school psychologists’ diagnostic practices and
beliefs related to medication monitoring and/or knowledge of child psychopharmacology.
The researchers conducting these studies have obtained a usable response rate ranging
from 37% (Carlson, Demeray, & Hunter, 2006) to 64.7% (Guereasko-Moore, DuPaul, &
Power, 2005). Given the wide variation in response rates across similar studies the goal
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for this study was to obtain a usable response rate of at least 50% with a minimum
response rate of 35%. As a result, surveys were mailed to the entire sample listed as
currently working in a school setting. A 50% return rate would then yield 136 returned
surveys. In order to arrive at this specific number of surveys, a power analysis was
conducted utilizing Cohen’s (1988) statistical formula. A minimum return rate of 35%
yielding 96 surveys would result in adequate power (> .80).
Respondent Information
The number of respondents for this study and percentage of the total sample are
presented in Table 2. A total of 166 of the 273 potential respondents replied to either the
first or second mailing, resulting in a return rate of 61%. A total of 26 respondents
checked a box at the beginning of the survey indicating they did not currently work in a
school and returned the blank questionnaire.
The response rate for the first mailing was significantly higher than the rate for
the second mailing. Specifically, 134 out of 273 respondents returned the questionnaire
after the first mailing. The researcher utilized specific numeric codes on the outside of
each return envelope in order to determine if the respondent was mailing back the
questionnaire from the first or second mailing. This represented a 49% response rate for
the first mailing. For participants sent a second questionnaire, 32 out of 139 initial nonresponders returned a questionnaire. This represented a 23% response rate for the second
mailing.
A total sample of 166 questionnaires and 140 useable surveys (i.e., participants
indicating they did not work in a school were excluded from analyses) was considered
within the acceptable range for the analyses in order to answer each research question.
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The power achieved for this sample was calculated to be adequate (> .80) based on
Cohen’s (1988) statistical formula. Additionally, when comparing response rates for the
current study to previous research the overall response rate is within the range of other
empirical studies.
Table 2
Respondent Data

Item

n

% of Total Sample

Total questionnaires sent-1 mailing

273

100%

Total questionnaires returned-1st mailing

134

49%

Total questionnaires sent -2nd mailing

st

139

51%

nd

Total questionnaires returned-2 mailing

32

23%

Total of respondents not eligible

26

9.5%

Total number of non-responders

107

39%

Total useable questionnaires

140

51%

Total returned surveys (including ineligible)

166

61%

Demographic Information
Demographic information was collected from all respondents in addition to
questions regarding types of degrees held outside the field of school psychology, years
practicing, student to school psychologist ratio, and percentage of time working with
various K-12 grade levels including time spent in non-student activities (e.g., district
office). A summary of demographic information collected is presented in Table 3. The
majority of the sample was female (84.3%). The ethnicity of the sample was largely
White, not of Hispanic origin (81.4%). The sample closely represents the demographic
information collected by the National Association of School Psychologists (NASP; 2010)
with some noteworthy exceptions. Specifically, in the study sample 81.5% of respondents
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indicated holding a specialist or master’s +30 degree whereas in the NASP sample this
value was 45.76%. Additionally, in the study sample the reported school psychologist to
student ratios are significantly higher.

Respondents indicated 38.9% had a school

psychologist to student ratio of 1: >3,000 compared to only 4% in the NASP sample.
Given that the sample was selected from members of the Florida Association of
School Psychologists, the entire sample reported practicing in the State of Florida. The
vast majority of respondents reported working full-time (95%) while 0.7% reported parttime employment, 2.1% reported employment as a contractual/independent consultant,
and 2.1% did not respond to this question. Regarding degree level, the majority of
respondents (81.5%) reported holding a specialist or master’s +30 degree in school
psychology while 14.3% reported holding a doctorate. A lesser percentage reported
holding a master’s degree only (4.3%). A question was included in the survey regarding
graduate degrees held in fields outside school psychology.

Approximately 14% of

respondents listed degrees held in clinical psychology, counseling psychology, special
education, educational leadership, and other fields such as information technology. All
respondents reported holding master’s degrees in other fields with the exception of one
respondent reporting a doctorate in educational leadership.
Examining the years of experience of respondents revealed most respondents had
greater than six years of experience practicing as a school psychologist. Specifically,
89.3% of respondents had more than 10 years experience practicing as a school
psychologist while only 10.7% reported less than five years in practice. The school
psychologist to student ratio varied greatly across respondents.

The lowest school

psychologist to student ratio reported was 1:450 while the highest was 1:8,500. The
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mean school psychologist to student ratio was 1:2,092. Respondents were asked to
indicate their primary geographic setting in which they work (i.e., urban, suburban, or
rural). Respondents indicated 25% working in an urban, 49.3% in suburban, and 25.7%
in rural locations. Regarding the population of students served, responses varied. The
most frequent work setting was elementary school (56.5%), followed by middle school
(17.5%), and high school (15.3%). Some respondents reported working in a Pre-K
setting (8.5%) for some portion of their time while others reported working in a nonstudent allocation such as being assigned to the district office (2.2%) for part of their
time. One respondent indicated working full-time in a non-student allocation. As a result,
the data from that respondent were excluded in analyses due to no direct student contact
being reported.

The demographic characteristics of the sample compared to the

information provided by NASP are displayed in Table 3.
Table 3
Comparison of School Psychologists’ Demographic Categories of Current Study to NASP
Membership (2010)

Current Study

NASP (2010)

n = 140

n = 1272

Male

15.7%

21.9

Female

84.3%

78.1

Black/African American

8.6%

3%

Asian American/Pacific Islander

1.4%

1.3%

Native American/Alaskan Native

0%

.6%

White/Caucasian

81.4%

90.7%

Hispanic/Latino

8.6%

3.4%

Demographic Information
Gender

Ethnicity
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Other

0%

1%

0%

0%

Master’s

4.3%

25.06%

Master’s +30/Specialist

81.5%

45.76%

Doctorate

14.3%

24.17%

0-5 years

10.7%

30.3%

6-10 years

20%

15.9%

11-15 years

31.4%

14.3%

16+ years

37.9%

27.6%

<1000:1

22.1%

43.6%

<1500:1

23.7%

67.9%

>2000:1

15.3%

14.4%

>3000:1

38.9%

4.0%

25%

25.6%

Suburban

49.3%

43.4%

Rural

25.7%

24.0%

Highest Degree in School Psychology
Bachelor’s

Years Practicing as a School Psychologist

School Psychologist to Student Ratio

Primary Work Location
Urban

Materials
A cover letter, included with the survey, presented the purpose of the study,
estimated time to complete the survey, provided the principal investigator’s (PI) contact
information, and an explanation of the incentives for completion of the survey were
included with the survey (Appendix A). Specifically, in order to increase the response
rate, each respondent received a U.S. currency one dollar bill enclosed in the survey as an
incentive to return a completed survey. Previous research demonstrates that offering an
upfront incentive for completing a survey increases the useable response rate (Dillman,
Smyth, & Christian, 2009; Erwin & Wheelright, 2002; Tuten, Galesic, & Bosnjak, 2004).
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The survey (see Appendix C) included a section requesting demographic
information along with Likert-type rating scales. Participants were asked to provide
demographic data including their gender, ethnicity, job status (i.e., full-time, part-time,
contractual), highest degree in school psychology, highest degree earned not in school
psychology, number of years practicing as a school psychologist, type of schools served,
student to school psychologist ratio, and percentage of time working with students at
different grade levels. Following the demographic section, the survey was divided into
five primary areas of school psychologists’ practices related to medication monitoring
and beliefs of effectiveness, efficacy, and feasibility of methods used to monitor
medications. Specifically, the survey assessed (a) the self-reported training related to
medication monitoring, (b) the types of disorders students are diagnosed with for which
school psychologists are monitoring medications, (c) the procedures utilized to monitor
the effects of medications, (d) the effectiveness, acceptability, and feasibility of
medication monitoring procedures, and (e) facilitators and barriers to monitoring
medications in schools.
Participants were asked a variety of “yes/no”, Likert type and frequency of use
questions to gather data. Participants were asked whether they have been involved in
monitoring the effects of medications for a student with whom they work. If the
participants answered “yes”, they were directed to continue answering several in-depth
questions assessing the types of disorders for which the school psychologist was
monitoring medications, and the procedures utilized to monitor medications. All
participants were asked to indicate their perceptions related to the degree to which
various methods of monitoring medications are effective, acceptable, and feasible in the
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school setting. All participants were asked to indicate their perceptions related to the
degree to which various variables are facilitators and barriers to monitoring medications
in school settings. The estimated time to complete the survey was between 15-20
minutes.
Procedures
The first step in conducting this study was to develop the survey itself. The
investigator reviewed the extant literature related to this topic to determine gaps in the
current literature and areas in need of further research. Specifically, as stated in
the literature review, one known study has examined school psychologists’ current
practices related to medication monitoring (Guerasko-Moore & DuPaul, 2005).
However, that study was limited to examining medication monitoring practices related to
Attention- Deficit/Hyperactivity Disorder (ADHD) and medications prescribed to treat
the symptoms of ADHD. In developing the current survey, the researcher examined
surveys utilized in previous studies on this topic. The researcher built on previous
research and expanded the scope of medication monitoring practices to all psychotropic
medications that are prescribed to school-age children and adolescents. The final survey
consisted of 22 questions, divided into four sections. Each section utilized fill in the
blank, multiple choice, and Likert-type question formats to gather data. The first section
contains 11 questions related to gender, age, ethnicity, professional background, state in
which the psychologist is currently employed, employment setting, employment type
(i.e., part or full-time, contractual), types of students with whom the school psychologist
works (i.e., grade levels), and the school psychologist to student ratio. Additionally, at
the beginning of the survey, respondents who did not work in schools at all were asked to
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check a box indicating this and return the survey in the postage-paid envelope. The
second section consisted of questions related to previous training in medication
monitoring, philosophy of graduate training program, frequency of medication
monitoring, and types of medications monitored. To ensure clarity, operational
definitions were given for overall philosophy of graduate training programs broken down
into four categories. Each category ranged from extremely traditional (e.g., primary focus
is on psychoeducational assessment for eligibility in special education programs) to
extremely non-traditional (e.g., primary focus is on linking assessment to intervention
and little focus on psychoeducational assessment solely for eligibility in special education
programs). The third section consisted of questions related to the types of methods
utilized to monitor medications. To collect data on the frequency and number of students
a school psychologist monitors per year, respondents selected from numeric ranges. To
collect data on the types of medications school psychologists are monitoring, a
comprehensive list of psychotropic drug categories was presented. The fourth section
consisted of questions assessing specific procedures school psychologists use to collect
medication monitoring data as well as with whom and the frequency in which the
information is shared. Additionally this section assessed perceived facilitators and
barriers to engaging in medication monitoring.
Numerous drafts of the survey were reviewed by an expert panel consisting of
school psychology faculty members with expertise in pediatric school psychology,
graduate students with experience in conducting surveys, and a faculty member with
expertise in measurement and survey development. Based upon the feedback from this
panel, revisions were made to the survey with respect to clarity of the questions and

57

response options, as well as overall organization of the survey contents. Specifically, a
number of changes were made to the survey itself based on recommendations from the
panel. The length of the survey was shorted from 26 to 22 questions and the format of
questions was changed from forced choice response type questions to an open-ended item
for question 22 that asked respondents about facilitators to medication monitoring. The
reason for this was to counterbalance question 21 which asked about barriers to
medication monitoring and respondents were asked to select from a list which they felt
were barriers. It was hypothesized by the panel and researcher that extant research has
identified barriers school psychologists face in practice but a paucity of data exists on
what facets facilitate medication monitoring. Operational definitions were given at key
points in the survey to help ensure participants understood how medication monitoring is
being defined in this study to ensure accurate results. In section 1 (background
information), a question (item 6) was added based on a recommendation from a panel
member to ask participants about their highest graduate degree earned that was not in
school psychology. This question was added based on information gathered during the
previous NASP membership survey which also added that question to ascertain what
other degrees school psychologists possess. The cover letters were also modified in
several ways to help ensure clarity and to increase the potential response rate by
shortening the letter(s). Specifically, the panel recommended a more clear definition of
medication monitoring in the first paragraph of both the initial and follow-up letters as
well as attempting to keep the letter to one page in length.
The next step in the survey development process was to conduct a pilot study of
the cover letter and survey with 26 practicing school psychologists to gather additional
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feedback on survey organization and clarity. In addition, seven of those practicing school
psychologists were randomly selected to be contacted by phone and interviewed about
the clarity of questions on the survey. They also were asked how they would answer
each question to ascertain whether the questions would glean the anticipated information.
The researcher spent approximately 20 to 30 minutes with each participant going through
the survey and asking them how they would answer questions. Overall, the answers
school psychologists gave were consistent with the data the researcher desired to collect.
In addition, participants in the pilot study were asked to record the total number of
minutes required to complete the survey. Participants estimated the total time to complete
the survey was between 15-20 minutes. Feedback obtained from participants in the pilot
study was used to finalize the survey and cover letter. A number of specific changes
were made to both the survey and cover letters based on feedback from the panel of
practicing school psychologists. Specifically, three of the seven school psychologists
being interviewed by phone consistently appeared to misunderstand one item. In item 21,
which queries respondents regarding barriers to medication monitoring, participants
appeared confused by the meaning of “lack of community support”. As a result, the
researcher added “e.g., collaborative relationships with mental/physical health providers
in the community” based on feedback from members of the panel. In item 10 which asks
“primary location of current work site (please choose one)” several members of the panel
recommended bolding and placing in italics the word “one” so that respondents would
only check a single box. Members of the panel of practicing school psychologists also
had various formatting recommendations including bolding and increasing the font size
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of directions to skip items (i.e., item 12) if the question did not pertain to them (e.g.,
respondent has no medication monitoring training).
Approval to conduct the study was obtained from the University of South Florida
(USF) Institutional Review Board (IRB) prior to commencement of data collection. This
assisted in ensuring that all possible and necessary precautions were taken to protect
human research participants. Once approval was obtained from the USF IRB, approval
from the Florida Association of School Psychologists (FASP) was obtained. A separate
application detailing the scope and nature of the proposed study, research questions, and
risks versus benefits to participants was provided to FASP. Upon approval from FASP,
the researcher obtained the FASP membership directory of practicing school
psychologists via an electronic database of mailing addresses for each participant. Two
separate mailings were conducted to ensure the highest return rate possible. Specifically,
all selected participants were included in an initial mailing that included a cover letter
(Appendix A), survey (Appendix C), U.S. currency dollar bill (for an incentive), and a
self-addressed postage-paid envelope. A unique code number was utilized on the front of
each survey in order to determine if a participant needed to be mailed a second survey for
non-response to the first one. After the first mailing, participants who had not responded
within one month of the initial mailing were mailed a second survey as well as a followup cover letter (Appendix B) encouraging them to return their completed survey.
A database was created using Microsoft Excel in order to enter data as surveys
were received. The primary researcher set up the database and developed specific codes
for entering each item from the survey. Specifically, each item on the survey was coded
with a specific number to indicate the respondent’s answer to a question. The data were
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then entered by the primary researcher. Once all data had been entered, every tenth
survey was checked for errors with a member of the research team. If an error was
found, the survey entered prior to and after the randomly selected survey was also
checked for errors. All errors were recorded in a separate error log in order to report the
results. If an incomplete survey was received, the researcher examined the survey and
determined if it should be entered into the database. The researcher utilized the
following criteria in order to make the determination whether or not to enter the
incomplete survey data: (a) if the demographic data were incomplete the survey was
excluded from the database as many of the analyses required the combination of answers
to questions in sections II-IV as well as demographic data, (b) if the demographic data
were complete and portions of sections II-IV were incomplete, the primary researcher
made a determination whether to enter the incomplete survey into the database based on
the amount of information missing. Specifically, the researcher used his judgment
whether the survey would provide additional information in the data set or if too much
information was missing to contribute to the overall study. This occurred in one instance.
The respondent left multiple areas of the survey blank including questions related to
training in medication monitoring as well as their perceptions of barriers and facilitators.
As a result, due to the necessity of the missing information in order to carry out analyses,
that respondent’s survey was not included in the data set.
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Chapter Four
Results
This chapter begins with a discussion of how the survey data were entered into the
database and the precautions taken to ensure the integrity of these data.

Each research

question is then presented along with the specific analyses conducted to address the
questions.
Treatment of the Data
All data were initially entered into a Microsoft Excel spreadsheet during the Fall
of 2011 by the researcher. Data were then checked by another member of the research
team for data entry errors. Specifically, data were analyzed using the Statistical Package
for the Social Sciences (SPSS) Version 19 (SPSS Inc., 2010) for values falling outside
expected ranges following data entry. If a value was found to be outside the expected
range, the survey was checked and the correct response entered into the dataset. Next,
the researcher and a member of the research team reviewed every tenth survey manually
to check for data entry errors. If an error was found the surveys before and after were
also checked for data entry errors. At the conclusion of the process 24% of the surveys
were reviewed for data entry errors. Data entry errors were calculated to have occurred
on 0.5% of the surveys checked. The small amounts of errors found were then manually
corrected in the Excel spreadsheet. SPSS was used to conduct analyses in order to
address each research question.
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Research Question 1: Do school psychologists believe medication monitoring is a
role in which they should be engaged?
For the purpose of this study, the survey instrument defined medication
monitoring as follows: “Medication monitoring is defined as including the following
activities (not an exhaustive list): Consultation with classroom teacher(s) and
paraprofessionals, utilization of behavior rating scales, behavior observations, review of
work samples or curriculum-based assessments”. This definition was provided in bold
face type to respondents on the second page of the survey prior to being asked questions
related to medication monitoring. To address this research question, the frequencies of
responses to question 14 on the survey instrument were examined. Specifically, question
14 asked “Please indicate your opinion to this statement: Monitoring the effects of
psychotropic medications for students with emotional and behavior disorders (e.g.,
ADHD, depression, anxiety) and other disorders is a role in which school psychologists
should be involved”. Respondents could select any one of the following responses to this
question: “Strongly Disagree”, “Disagree”, Neither Agree nor Disagree”, “Agree”, and
“Strongly Agree”. Descriptive statistics are presented in Table 4 and the percentages
respondents endorsed by category (e.g., Strongly Disagree, Strongly Agree) are presented
in Table 5. Overall, the majority of respondents (74.3%) indicated they “Agree” or
“Strongly Agree” that medication monitoring is an appropriate role for school
psychologists.
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Table 4
Descriptive Statistics of School Psychologists’ Beliefs Related to Medication Monitoring
(n =140)
Medication Monitoring
Agreement

n
140

M
3.93

95% CI
3.79-4.07

SD
0.85

Sk
-0.78

Ku
0.95

Range
1-5

Note. The scale of the medication monitoring agreement variable is as follows: 1=Strongly Disagree, 2=
Disagree, 3= Neither Agree nor Disagree, 4= Agree, 5= Strongly Agree.

Table 5
Response to Role of School Psychologists in Medication Monitoring (n =140)
Rating

n

Percent

Strongly Agree

35

25%

Agree

69

49.3%

Neither Agree or Disagree

29

20.7%

Disagree

5

3.6%

Strongly Disagree

2

1.4%

Research Question 2: What is the relationship between school psychologists’ beliefs
regarding medication monitoring as part of their role and their likelihood of
engaging in medication monitoring in practice?
In order to analyze data pertaining to this question, respondents’ answers to
survey questions 14 and 16 were examined. Specifically, respondents were asked in
question 14 to indicate their opinion to the following statement: “Monitoring the effects
of psychotropic medications for students with emotional and behavior disorders (e.g.,
ADHD, depression, anxiety) and other disorders is a role in which school psychologists
should be involved”. A Likert type scale ranging from “Strongly Disagree” to “Strongly
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Agree” was utilized. For survey question 16, respondents were asked the following:
“How frequently do you monitor the effects (beneficial or negative) of a psychotropic
medication for students with whom you work?” Response choices for this question were
“Annually, “Quarterly (i.e., fall, winter, spring)”, “Once per month”, “Once per week”,
“Daily”, “2-5 times per day”, and “5+ times per day”. Participants were also directed to
review the operational definition of medication monitoring provided at the beginning of
the survey in order to answer this question.
In order to address this research question a Spearman rank order correlation
coefficient was calculated for data collected in questions 14 and 16 on the survey. The
data collected from question 14 based on a five-point Likert scale was utilized in the
analysis. Specifically, all respondents’ data were used (i.e., respondents who chose
“Strongly Disagree”, “Disagree”, Neither Agree nor Disagree”, “Agree”, and “Strongly
Agree”). Also, the data collected from item 16 was also utilized (i.e., “Annually,
“Quarterly (i.e., fall, winter, spring)”, “Once per month”, “Once per week”, “Daily”, “2-5
times per day”, and “5+ times per day”) in the analysis. Due to the nature of the
variables, (i.e., ordinal data) the Spearman method was chosen to carry out the analyses.
The results are presented in Table 6. Overall, there is a relatively weak relationship
between respondents’ beliefs related to medication monitoring and frequency of
medication monitoring. This not surprising as many respondents reported believing that
medication monitoring is a role they agree with, yet had not engaged in.
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Table 6
Spearman’s Rho Correlation between Beliefs in Medication Monitoring and Actual
Reported Practices (n = 77)
Variables

1.

1. Medication monitoring beliefs

−

2. Frequency of medication monitoring practices
M

2.

0.24*

−

2.91
1.02

SD

Note. The scale of the variable “Medication monitoring beliefs” was assessed using the following:
1=Strongly Disagree, 2=Disagree, 3=Neither Agree nor Disagree, 4=Agree, 5=Strongly Agree. The scale
for the variable “Frequency of medication monitoring practices” was assessed using the following:
1=Annually, 2= Quarterly, 3= Once per month, 4=Once per week, 5 = Daily, 6= 2-5 times per day, 7 = 5+
times per day.
*p < .05.

In order to further analyze data pertaining to this research question, respondents’
answers to survey questions 14 and 15 were also examined. In question 14, respondents
were asked to indicate using a five-point Likert scale, their opinion on whether
medication monitoring is a role in which school psychologists should be involved. For
survey question 15, respondents were asked to indicate “yes” or “no” to the following
question: “Have you been involved in monitoring the effects (beneficial or negative) of a
psychotropic medication in any manner for a student with whom you work?”
Respondents were also directed to review the definition of medication monitoring in the
beginning of the survey before answering question 15.
An independent samples t-test was conducted to compare group means for
respondents who reported being involved in medication monitoring practices (Item #15)
and their beliefs regarding medication monitoring (Item # 14). The results are presented
in Table 7. There was a significant difference between respondents who endorsed “yes”
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(M = 4.11, SD = 0.85) versus “no” (M = 3.61, SD =0.77) for whether they engage in
medication monitoring in their agreement that medication monitoring is a role in which
school psychologists should be involved, t (137) = -3.48, p < .001. Levene’s test was
not significant, therefore equal variances are assumed.
Overall, there is a relatively weak relationship between school psychologists’
beliefs regarding medication monitoring and their actual reported practice. However,
when comparing group means between school psychologists who reported engaging in
medication monitoring versus those who did not, a statistically significant difference was
found.
Table 7
Independent Samples t-test Examining Beliefs Regarding Medication Monitoring and
Reported Involvement in Medication Monitoring (n = 137)
Yes

No

M
(SD)

M
(SD)

t

Agreement with Medication Monitoring 4.11

3.61

-3.48

0.85

0.77

Medication Monitoring Involvement

df

137

Sig
(2tailed)
.001

Note. The scale of the variable “Medication monitoring involvement” was assessed by respondents
indicating either “Yes” or “No”. The scale of the variable “Medication monitoring beliefs” was assessed
using the following: 1=Strongly Disagree, 2=Disagree, 3=Neither Agree nor Disagree, 4=Agree,
5=Strongly Agree.
*p < .05.

Research Question 3: What are the current medication monitoring practices of
school psychologists? (a) What types of data are collected when engaged in
medication monitoring? (b)What is the frequency (e.g., daily, weekly, or monthly)
that medication monitoring data are collected? (c) What is the frequency (e.g, daily,
weekly, or monthly) that medication monitoring data are shared? (d) With whom is
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medication monitoring information shared (e.g., primary care provider, parents,
school-based intervention team, teachers)?
Question 3a: What types of data are collected when engaged in medication
monitoring?
Responses from item 20 were examined to address this research question. This
item asked respondents to indicate which procedures they used to monitor medications as
well as how often each procedure was used. The categories included behavior rating
scales, direct behavior observations, child and teacher interviews, work samples,
curriculum based assessments, and grades. A response category of “Other” was included
with item 20 so respondents could list types of data collected that were not included on
the survey. Respondents who listed a category under “Other” (n = 18) did not report a
frequency with which they utilized the particular method. As a result, N/A is reported.
Table 8 presents the percentages of respondents who reported using each method of data
collection. Of note, the categories in Table 8 are not mutually exclusive. Respondents
were able to report the use of more than one method in the practice of medication
monitoring. Overall, respondents reported utilizing a multitude of methods in medication
monitoring rather than relying on a single method. Methods endorsed by 50% or more of
the respondents included direct behavior observations, teacher rating forms, child
interviews, and teacher interviews.
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Question 3b: What is the frequency (e.g., daily, weekly, or monthly) that medication
monitoring data are collected?
Data from survey question 20 were used to analyze the results for this question
(see Table 8). The majority of respondents reported utilizing each method one time per
month or less overall but did report using a variety of methods (e.g., teacher interviews,
child interviews, review of work samples). Some (21%) of respondents reported utilizing
teacher interviews every other week (e.g., bi-weekly) while approximately 15% reported
using direct behavior observations on a bi-weekly basis and 14% on a weekly basis. A
very small percentage (less than 2%) reported using direct behavior observations and
curriculum-based assessment procedures on a daily basis. Some respondents utilized the
“Other” category reporting a variety of medication monitoring methods used to collect
data. Specifically, consultations with the school nurse, daily behavior reports from
teachers, response to counseling sessions, and statewide data from standardized tests
were reported. Overall the number of respondents using the “Other” category was lower
than those who utilized the provided categories (i.e., < 20).
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Table 8
Frequency of Medication Monitoring Practices (n = 77)

Medication Monitoring

n

Percentage

Method

<1 time

1x

Approx 1x

1x

month

month

every 2

week

Daily

N/A or 0
times

weeks
Teacher rating forms

71

50.7%

54..9%

22.5%

12.7%

1.4%

0%

8.5%

Direct behavior

74

52.9%

24.3%

44.6%

14.9%

13.5%

1.4%

1.4%

69

49.3%

62.3%

17.4%

8.7%

1.4%

0%

10.1%

49.3%

52.2%

30.4%

7.2%

1.4%

0%

8.7%

49.3%

53.6%

14.5%

4.3%

4.3%

0%

23.2%

observations
Parent rating forms
Parent interviews
69
Child self-report rating
scales

69

Child interview

70

50%

42.9%

25.7%

11.4%

8.6%

0%

11.4%

Teacher interview

73

52.1%

20.5%

45.2%

20.5%

9.6%

0%

4.1%

Permanent products

66

47.1%

31.8%

25.8%

10.6%

6.1%

0%

25.8%

Curriculum based

66

47.1%

33.3%

16.7%

10.6%

6.1%

1.5%

31.8%

69

49.3%

50.7%

26.1%

10.1%

1.4%

0%

11.6%

4

3.0%

N/A

N/A

N/A

N/A

N/A

N/A

Discipline records

3

2.0%

N/A

N/A

N/A

N/A

N/A

N/A

Statewide reading

2

1.4%

N/A

N/A

N/A

N/A

N/A

N/A

Response to counseling

1

.07%

N/A

N/A

N/A

N/A

N/A

N/A

Daily behavior reports

8

6.0%

N/A

N/A

N/A

N/A

N/A

N/A

assessment
Grades
Other
Consultation with
school
nurse

assessment

from teacher

Note. The scale for the variables with the exception of the category “Other” was assessed using the
following: 1=Strongly Disagree, 2=Disagree, 3=Neither Agree nor Disagree, 4=Agree, 5=Strongly Agree.
The scale for the category “Other” was free response and the n along with the percentage of respondents
who endorsed each are presented.
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Question 3c: What is the frequency (e.g., daily, weekly, or monthly) that medication
monitoring data are shared?
To address this research question, responses from item 19 which asked “when you
engage in medication monitoring, in general with whom and how often do you share the
information?” were examined. The categories included (“< 1 time per month”, “1 time
per month”, “Approximately 1 time every two weeks (i.e., bi-weekly)”, 1 time a week”,
“Daily”, and “N/A or zero times”. Table 9 presents the frequencies displayed as
percentages that respondents reported in sharing medication monitoring information as
well as with what entity it was shared. The majority of school psychologists reported
sharing medication monitoring information with parents, teachers, prescribing physicians,
and the school-based intervention team typically one time per month or less. However,
some school psychologists reported sharing of information on a more frequent basis.
Specifically, when sharing information with parents, nine percent of school psychologists
reported sharing information bi-weekly and seven percent reported sharing information
weekly. When sharing information with teachers, 15 percent reported sharing
information weekly as well as bi-weekly, and three percent reported daily sharing of
information. When sharing information with the prescribing physician, one percent
reported bi-weekly sharing of information and no respondents reported weekly or daily
sharing information. When sharing information with the school-based intervention team,
18 percent reported sharing information bi-weekly, five percent weekly, and one percent
daily. Respondents who utilized the “Other” category did not list the frequency in which
they share information, only the entity with which they share the information. The next
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section will discuss which entities respondents report sharing information with in more
detail.
Question 3d: With whom are medication monitoring data shared?
In order to address this research question responses from item 19 were examined.
The potential categories included Parents, Teachers, Prescribing Physicians, Schoolbased intervention teams, and a category for “Other”. Table 9 presents the results.
Overall, respondents indicated sharing information with Parents, Teachers, Prescribing
Physicians, and the School-based intervention team relatively equally (range is 52.1%54.2%). Regarding responses to the “Other” category, 9% of respondents indicated they
share medication monitoring information with a child’s therapist, 3% reported sharing
information with the school nurse and one respondent (0.02%) indicated they shared
information with an outside agency.
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Table 9
Frequency of Sharing Medication Monitoring Information and with Whom it is Shared (n
= 77)

Sharing of Information

n

Percentage

<1 time

1x

Approx 1x

1x

month

month

every 2

week

Daily

N/A or 0
times

weeks
Parents

76

54.2%

40.8%

40.8%

9.2%

6.6%

0%

2.6%

Teacher

75

53.5%

30.7%

37.3%

14.7%

14.7%

2.7%

0%

Prescribing Physician

73

52.1%

39.7%

12.3%

1.4%

0%

0%

46.6%

School-based Intervention

74

52.8%

25.7%

41.9%

17.6%

5.4%

1.4%

8.1%

Outside care agency

3

0.02%

N/A

N/A

N/A

N/A

N/A

N/A

Mental

13

9%

N/A

N/A

N/A

N/A

N/A

N/A

4

3%

N/A

N/A

N/A

N/A

N/A

N/A

Team
Other

health/therapists
Nurse (school)

Research Question 4: What types of training (pre-service vs. in-service) do school
psychologists receive in the practice of medication monitoring?
To address this research question, responses from survey item 12 were examined
which asked “Have you received training at any time in the past on monitoring the effects
of psychotropic medications in students?” Respondents had the option of answering
either “yes” or “no” to this question. If respondents indicated “yes”, they were then
directed to indicate what types of medication monitoring training they have received from
a list of potential types of trainings. Overall, 63.3% (n = 88) of respondents reported
receiving some training related to medication in the past. The results are presented in
Table 10.
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Table 10
Percentage of Respondents with Training in Medication Monitoring (n = 140)
Medication Monitoring Training

n

Percent.

95% Confidence Interval

Yes

88

63.3%

57.18-69.42%

No

51

36.7%

26.14-47.26%

Table 11 illustrates the descriptive statistics regarding the types of medication
monitoring training (e.g., in-service, reading of scholarly journals, and graduate courses
containing a component on medication monitoring) respondents reported receiving at any
point in the past. The majority of respondents reported receiving a variety of types of
training. The amount of training reported by respondents varied considerably.
Specifically, the means and standard deviations for each training category from highest to
lowest are as follows: Personal reading of scholarly journal articles in hours (M =17.43,
SD = 22.74), Personal reading of textbooks in hours (M = 14.32, SD = 17.25), In-service
training (M = 3.73, SD = 4.08), attending professional conferences (M =3.41, SD = 3.63),
online training (M = 1.93, SD = 3.03), and graduate courses containing a component on
the topic of medication monitoring (M = 1.65, SD = 2.03). Overall, respondents reported
the greatest amount of training in personal reading of scholarly articles and textbooks.
However, the scale for those two variables was in hours while the other types of training
were measured in number of trainings or graduate courses. Therefore, comparisons must
be made carefully.
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Table 11
Descriptive Statistics of Types of Medication Monitoring Training (n =77)
n

M

SD

Sk

Ku

Range

In-service training

75

3.73

4.08

2.41

6.42

0-20

Online training

59

1.93

3.03

1.59

1.56

0-12

Professional
conferences

71

3.41

3.63

2.90

10.93

0-20

Graduate courses

66

1.65

2.03

2.08

3.41

0-8

Personal reading of
scholarly journals
(hours)

72

17.43

22.74

2.40

5.85

0-100

Personal reading of
textbooks (hours)

71

14.32

17.25

2.40

7.92

0-100

Other

4

N/A

N/A

N/A

N/A

N/A

Consultation
with physicians

Note. The scale for each of the variables is as follows: In-service training, online training, professional
conferences, graduate coursework, personal reading of scholarly journals and textbooks, and “other” were
continuous variables measured by the number of trainings, conferences, courses, and hours spent reading
reported.

Research Question 5: What are the perceived barriers and facilitators to medication
monitoring?
Responses from item 21 (barriers) and item 22 (facilitators) were used to answer
this research question. Item 21 required respondents to answer the following question:
“To what extent do you agree or disagree that each of the following factors is a barrier to
school psychologists monitoring psychotropic medications students are taking?”
Respondents were provided with a list of 11 factors, including one that allowed them to
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write in an “Other” option, and were asked to indicate the extent to which they agreed or
disagreed to the factor on a 5-point Likert scale ranging from “Strongly Agree” to
“Strongly Disagree”. The means and standard deviations represent respondents as a group
reporting their opinion on the degree to which they agreed or disagreed that each factor is
a barrier. “Strongly Disagree” would be represented as a 1 while “Strongly Agree” is at
the highest end of the scale at 5. The results of respondents’ ratings are presented in
Table 12. Three factors were rated by respondents as the largest barriers to medication
monitoring compared to the remaining eight. Lack of time was reported to be the largest
barrier (M = 3.60, SD = 1.13, n = 137). Lack of community support was listed as second
(M = 3.42, SD = 1.07, n = 137), and insufficient knowledge regarding how to monitor
medications was third (M = 3.10, SD = 1.19, n = 137).

The remaining eight factors were

rated fairly evenly on whether they were viewed as a barrier. Specifically, means for
each were below 3.0 indicating respondents were neutral regarding whether these factors
served as barriers to medication monitoring.
Some respondents listed their own barriers to medication monitoring under the
category for “Other”. Although the number of respondents using the “Other” category is
low (n = 37), responses included perceptions that primary care pediatricians prescribe the
greatest amount of psychotropic medications and have little training in monitoring,
situations where the student’s behavior improves and the need to actively monitor
decreases, and an overall unawareness of the school psychologist’s skill set related to
medication monitoring.
Survey item 22 utilized an open ended response format for respondents to list
factors they felt were facilitators to medication monitoring. A post-hoc thematic analysis
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based on recommendations from Lofland and Lofland (1995) was completed regarding
respondents’ reports of facilitators to medication monitoring. Specifically, each response
was carefully examined by the researcher and categories were developed. A total of 10
categories were created based on respondents’ reported perceptions of facilitators. These
categories sufficiently represent the perceptions of respondents with respect to facilitators
to medication monitoring based on recommendations from Lofland et al. (1995). Not all
respondents listed facilitators. Specifically, out of the total sample of 140 completed
surveys, 109 included information related to facilitators. This represents approximately
78% of respondents who answered the question related to facilitators to medication
monitoring. These results are presented in Table 13.
Regarding facilitators, respondents most frequently reported ongoing professional
training (26%) as an important facilitator to medication monitoring. This category could
include in-service training, professional conferences, online training, and supervision
from colleagues. The second most frequently listed facilitator was communication and
collaboration with the prescribing physician (21%). This category included the degree to
which the school psychologist and prescribing physician were able to communicate
effectively. The third most frequently listed category was including medication
monitoring activities on a student’s Individualized Education Plan (IEP). Specifically,
16.5% of respondents reported inclusion of specific tasks related to medication
monitoring as a facilitator. However, none of the respondents indicated whether this is a
practice that is currently occurring in their schools, or simply a recommendation that
including medication monitoring on a student’s IEP would facilitate the process of
collecting this type of data. Other facilitators listed were less frequently cited by
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respondents (< 6.5%) but did cover a fairly broad range of facilitators such as having
access to existing tools to make medication monitoring easier, less students on caseload,
and increased role flexibility.
Table 12
Perceptions of Barriers to Medication Monitoring (n = 140)

Factor

n

M

Sk

Strongly

SD

Ku

Disagree

Disagree

Neither

Agree

Agree

Strongly
Agree

nor Disagree
Lack of time

Insufficient knowledge

Lack of resources

Lack of teacher support

Lack of support of other

137

137

136

137

137

colleagues
Lack of parent support

Lack of administrative

137

137

support
Lack of support from

137

school psychologists’

3.60

-.67

1.14

-.43

3.10

-.25

1.19

-1.09

2.74

0.08

1.02

-1.09

2.23

0.69

.902

0.39

2.31

0.62

.920

0.09

2.65

0.21

1.02

-.66

2.58

0.21

.998

-.75

2.41

0.56

1.07

-.25

2.91

0.08

1.07

-.888

3.42

-.39

1.07

-.71

4%

N/A

5.1%

16.2%

13.2%

44.1%

21.3%

10.3%

26.5%

14.7%

39.7%

8.8%

9.6%

38.2%

22.1%

28.7%

1.5%

19.1%

50%

21.3%

8.1%

1.5%

16.8%

48.9%

22.6%

10.2%

1.5%

12.4%

35.8%

29.2%

19.7%

2.9%

13.1%

38.7%

27%

19.7%

1.5%

20.4%

38.7%

24.8%

11.7%

4.4%

8%

32.8%

25.5%

27.7%

5.8%

3.6%

20.4%

20.4%

41.6%

13.9%

N/A

N/A

N/A

N/A

N/A

supervisor
Teacher availability

Lack of community

137

137

support
Other
Pediatricians prescribe

5
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most psychotropic
medications, little training
in monitoring
Student’s behavior

11

8%

N/A

N/A

N/A

N/A

N/A

N/A

2

1.5%

N/A

N/A

N/A

N/A

N/A

N/A

13

9.42%

N/A

N/A

N/A

N/A

N/A

N/A

6

4.34%

N/A

N/A

N/A

N/A

N/A

N/A

improves, active
monitoring decreases
Belief monitoring is
completed informally with
no school psychologist
input
Unawareness of school
psychologist skill set
School is unaware of
student taking medication

Note. The scale for the variables with the exception of the category “Other” was assessed using the
following: 1=Strongly Disagree, 2=Disagree, 3=Neither Agree nor Disagree, 4=Agree, 5=Strongly Agree.
The scale for the category “Other” was free response and the n along with the percentage of respondents
who endorsed each are presented.
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Table 13
Perceptions of Facilitators to Medication Monitoring (n = 109)
Facilitator

n

Percent

Ongoing professional training

29

26.6%

Communication between school psychologist and
prescribing physician

23

21.1%

Collaboration between, school psychologist, teacher
and parents

16

6.0%

Graduate training

1

0.9%

More role flexibility

2

0.8%

Less students on caseload

7

6.4%

Easy to use method to monitor (e.g., checklists)

7

4.6%

Including on IEPs as progress monitoring
requirement
Time

18

16.5%

5

4.6%

Increased community support for medication
monitoring

1

0.9%

Note. The scale for the variables related to facilitators of medication monitoring was assessed using an
open-ended question “Given the listing of potential barriers in the previous question, please list what you
feel may be a facilitator to school psychologists monitoring psychotropic medications”. The items were
coded into 10 categories and the n along with percentage of respondents endorsing a facilitator in each
category are presented.

Research Question 6: What is the direction and strength of the relationship between
geographic location, degree level, training program philosophy, type of school
served, types of training related to medication monitoring, and the frequency of
medication monitoring by school psychologists?
Responses from survey items 10 (geographic location), 5 (degree level), 13
(training program philosophy), 11 (type of school served), and 12 (types of training
related to medication monitoring) in relation to item 16 (frequency of medication
monitoring) were examined in order to answer this research question. Spearman rank
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order correlation coefficients were calculated for all variables related to this research
question. The Spearman method was chosen due to the nature of the variables of interest
which included ordinal data. Prior to conducting Spearman rank order correlation
coefficients, preliminary analyses were performed to ensure there were no violations of
the assumptions of normality, linearity, and homoscedascticity. Specifically, a scatter
plot was generated to examine the data for outliers that fell outside of expected ranges
(i.e., exceeding three standard deviations) based on recommendations from Talbachnick
and Fidell (2007). The results are presented in Table 14. Overall, small to moderate
significant positive correlations were observed for respondents who reported practicing in
a rural school setting (rs = 0.39) and for those who received in-service training (rs = 0.38)
while a moderate negative correlation was observed for the variable non-student
allocation (rs = -.43). Other correlations for geographic location, types of school served,
and types of training were small to moderate but did not demonstrate a statistically
significant relationship with frequency of medication monitoring. In summary, the
results of the analyses indicate small to moderate relationships between some
demographic and training variables. However, the majority of intercorrelations were not
significant when using Cohen’s (1988) guidelines.
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Table 14
Intercorrelations between Demographic Variables and Medication Monitoring Practices
Variable

Frequency of Medication Monitoring

n

Spearman’s Rho

Sig. (2-tailed)

Geographic location
Urban

-.94

77
0.42

Suburban

0.12

77
0.29

Rural

0.39

77
0.03*

0.14

77
0.46

K-5

-.265

77
0.16

6-8

-.04

77
0.83

9-12

0.21

77
0.27

Non-student allocation

-.43

77
0.02*

In-service training

0.38

58
0.04*

Online training

-.001

45
0.99

Professional conferences

0.34

53
0.07

Graduate courses

0.06

48
0.77

Personal Reading Scholarly
Articles

0.27

56
0.16

Personal Reading Textbooks

0.25

56
0.19

Type of school (grade level)
Pre-K

* Correlation is significant at the p = 0.05 level (2-tailed).
Note. The scale for each of the variables is as follows: School setting was measured by geographic location
delineated as 1= urban, 2= suburban, 3= rural. Degree level: 1= Master’s, 2 = Masters +30, 3= Specialist,
4= Doctorate. Program philosophy was measured on a 5-point Likert scale delineated as 1= primarily
assessment focused, 2=somewhat assessment focused, 3= balanced between assessment and intervention
focus, 4= somewhat intervention focused, 5= primarily intervention focused. Grade level was measured in
percentages of time spent in each setting reported including a category for non-student allocation in which
no direct student contact occurs. In-service training, online training, professional conferences, and graduate
coursework were continuous variables measured by the number of trainings, conferences, and courses
reported. Medication monitoring frequency was measured on a scale of 1=annually, 2=quarterly, 3=once
per month, 4= once per week, 5= daily, 6=two to five times per day, 7= five or more times per day. The
sample sizes range from a minimum of 59 cases to a maximum of 140
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Additional Information
This section examines two further areas of interest in addition to the original
research questions. Predictive analyses examined how well degree level, training
program philosophy, geographic location, types of training reported related to medication
monitoring predict the frequency of medication monitoring by school psychologists.
Additionally, the types of disorders school psychologists reported monitoring
medications for were examined.
How well does degree level, training program philosophy, geographic location, types
of training reported related to medication monitoring predict the frequency of
medication monitoring by school psychologists?
To determine which variables were most predictive of the frequency of
medication monitoring by school psychologists, a simultaneous multiple regression
analysis was utilized. Specifically, respondents’ answers to items 5 (highest degree
earned), 10 (geographic location), 12 (types of training reported), 13 (philosophy of
training program), and 16 (frequency of medication monitoring) were examined. Some
survey items from each aforementioned variable were not included in the model if less
than 50 respondents completed the items (e.g., number of professional conferences and
online trainings attended). Respondents’ answers to item 10 were re-coded into dummy
variables due to their categorical nature in order to be entered into the regression model.
Prior to conducting the multiple regression analysis, preliminary analyses were conducted
to ascertain whether any violations of the assumptions of normality, linearity,
multicollinearity, and homoscedascticity occurred. First, the data were examined for the
presence of multicollinearity. When variables are highly correlated in a multiple
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regression analysis it becomes difficult to identify the unique contribution of each
variable in predicting the dependent variable (i.e., frequency of medication monitoring)
because the variables which are highly correlated are predicting the same variance in the
dependent variable. The values examined to determine if multicollinearity exists in the
model were tolerance and variance inflation factor (VIF). Tolerance is an indicator how
much variability of an independent variable is not explained by the other variables.
Tabachnick and Fidell (2007) recommend using a value of less than .10 as a guideline.
Specifically, if a value is very small (<.10) this indicates the multiple correlations with
other variables is very high. The VIF is interpreted as the inverse of tolerance and
Tabachnick et al. (2007) recommend values above 10 are a cause for concern. Two
independent variables exceeded these guidelines (personal reading of scholarly texts and
personal reading of textbooks and other sources). Due to the sensitivity of regression
analyses to violations of the assumption of multicollinearity, these variables were
combined in the model due to the very similar nature of each variable (i.e., personal
reading of scholarly journals and textbooks). Next, the data were examined for violations
of the assumptions related to normality, linearity, and homoscedascticity. Utilizing the
probability plots generated by SPSS and the regression standardized residual plot the data
were examined for violations to the aforementioned assumptions. The data fell in a linear
pattern suggesting no major deviations from normality. Additionally, the scatterplot
generated by SPSS was examined. Specifically, the standardized residuals were visually
examined and appeared to follow a rectangular pattern that did not deviate past 3.3 or 3.3 standard deviations from the mean. This pattern is desired as it suggests no violations
of the assumptions needed to utilize a multiple regression analysis (Tabachnick et al.,
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2007). The Mahalanobis distance was also examined to check for outliers. The critical
chi-square value based on the degrees of freedom was calculated to be 24.32 using an
alpha level of .001. Additionally, the value for Cook’s Distance was examined to
determine the degree to which the data identified as an outlier were having an undue
influence on the overall model. Tabachnick et al. (2007) recommend values that exceed
1 are potentially exhibiting undue influence on the overall regression model and should
be removed from the dataset. As a result, three data points fell significantly outside of
this value and were subsequently removed from the dataset. The results of the analysis
are presented in Table 15. An alpha level of .05 was used to determine statistical
significance. The regression analysis, predicting frequency of medication monitoring
from seven predictor variables, was not statistically significant, F (6, 44) = 0.86, p = .98,
R² = .11
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Table 15
Simultaneous Regression Analysis for Demographic Variables and Training Predicting
Medication Monitoring Practices (n = 51)
Variable

B

SE B

Constant

2.11

0.66

Degree level

0.08

0.20

Program philosophy

0.22

Urban Rural = reference
Suburban Rural = reference

β

t

p

3.17

0.03

0.06

0.39

0.69

0.15

0.25

1.49

0.14

-.01

0.41

-.01

-0.01

0.99

-.10

0.36

-.05

-.27

.78

In-service training

0.02

0.04

0.09

0.60

0.55

Personal Reading

0.02

0.04

0.07

0.46

0.64

School setting

R2

0.11

F

0.86

p < .05
Note: For the School Setting variable, Rural is denoted as the reference category. The scale for each of the
variables is as follows: Degree level: 1= Master’s, 2 = Masters +30, 3= Specialist, 4= Doctorate. Program
philosophy was measured on a 5-point Likert scale delineated as 1= primarily assessment focused,
2=somewhat assessment focused, 3= balanced between assessment and intervention focus, 4= somewhat
intervention focused, 5= primarily intervention focused. School setting was measured by geographic
location delineated as 1= urban, 2= suburban, 3= rural. In-service training, and personal reading, were
continuous variables measured by the number of trainings, conferences, hours spent reading, and courses
reported.

For what types of disorders do school psychologists monitor medications?
Participant responses from survey item 18 asking “In the last year, approximately
how many students have you monitored the effects of psychotropic medications for each
of the following disorders?” were examined. The response categories included AttentionDeficit/Hyperactivity Disorder, Oppositional Defiant Disorder, Depressive Disorders,
Anxiety Disorders, Autism Spectrum Disorders, Asperger’s Disorder, Bipolar Disorder,
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Tourettes Syndrome and/or Tic Disorders, Thought Disorders (e.g., schizophrenia),
Multiple Disorders (e.g., intellectual disability and disruptive behavior disorder), and a
category for “Other Disorders” in which respondents were asked to write in the name of
the disorder. Respondents were asked to indicate the number of students for whom
medication monitoring data were collected in the last year using a scale of: “0”, “1-2”,
“3-5”, “6-8”, and “9+”. The results are presented in Table 16. Overall, the majority of
respondents reported monitoring medications for a variety of disorders. It is important to
note the results in the table below are not mutually exclusive. Specifically, respondents
were able to report monitoring medications for a variety of disorders. The disorder with
the highest reported incidence of medication monitoring was AttentionDeficit/Hyperactivity Disorder (M =1.80, SD = 0.96, n = 75) while the lowest was
Thought Disorders (M = 0.27, SD = 0.660, n = 44). When examining the specific
percentages in Table 14 for each disorder which school psychologists reported
monitoring medications, most reported doing so for less than six students in the past
school year. Additionally, a small number of school psychologists utilized the category
“Other Disorders” and reported monitoring medications for seizure disorders and
Obsessive Compulsive Disorder. However, they did not indicate what frequency or the
number of students for whom they monitored medications.
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Table 16
Disorders for which School Psychologists Report Monitoring Medication in the Past
Year (n =77)
Number of Students
Disorder

Attention-Deficit/Hyperactivity

n

75

Disorder (ADHD)
Oppositional Defiant Disorder,

50

Conduct Disorder or other

M

Sk

SD

Ku

1.80

0.98

0.96

0.35

1.26

0.86

1.22

-.074

0.93

1.06

1.06

0.46

0.81

1.09

0.82

1.29

0.93

1.35

1.10

1.45

0.67

1.92

1.01

3.77

0.80

1.54

1.01

2.77

0.31

1.68

.563

2.02

0.27

2.69

.660

7.31

0.53

2.12

1.07

3.85

0

1-2

3-5

6-8

9+

1.3%

44.0%

37.3%

8%

9.3%

32%

34%

18%

8%

8%

43.5%

32.6%

13%

8.7%

2.2%

37.5%

50%

6.3%

6.3%

0%

43.6%

34.5%

12.7%

3.6%

5.5%

56.5%

30.4%

6.5%

2.2%

4.3%

41.2%

47.1%

3.9%

5.9%

2.0%

73.8%

21.4%

4.8%

0%

0%

81.8%

11.4%

4.5%

2.3%

0%

74.4%

9.3%

9.3%

2.3%

4.7%

externalizing disorder
Depressive Disorders

Anxiety Disorders

Autism Spectrum Disorders

Asperger’s Disorder

Bipolar Disorder

Tourettes Syndrome and/or Tic

46

48

55

46

51

42

Disorders
Thought Disorders

44

Multiple Disorders

43

Other Disorders
Seizure Disorders

2

1.5%

N/A

N/A

N/A

N/A

N/A

N/A

Obsessive Compulsive

4

3%

N/A

N/A

N/A

N/A

N/A

N/A

Disorder

Note. The scale for the variables with the exception of the category “Other” was assessed using the
following: 0= no students, 1-2=one-two students, 3-5=three to five students, 6-8=six to eight students,
9+=nine or more students. The scale for the category “Other” was free response and the N along with the
percentage of respondents who endorsed each are presented.
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Summary of Results
In summary, the results of this study found the majority of school psychologists
believe medication monitoring is an appropriate role (74.3%); however, intercorrelations
between school psychologists’ beliefs regarding medication monitoring and the
frequency of actual reported practice was low (rs = 0.24). School psychologists who
reported they engaged in medication monitoring in any amount held more favorable
views of this practice being an important role for school psychologists than those who did
not report engaging in medication monitoring at all. School psychologists reported using
a variety of methods to monitor medications (e.g., behavior rating scales, teacher
interviews, direct behavior observations) and utilized each method on average once per
month. However, some respondents (< 2%) did report engaging in medication
monitoring as frequently as once per day. With respect to receiving training related to
medication monitoring when broadly defined, over half the sample reported receiving
training at some time in the past (63.3%). The types of training included in-service
trainings, graduate coursework, and personal reading of scholarly articles. School
psychologists reported a number of barriers as well as facilitators to engaging in
medication monitoring. The most frequently reported barriers were lack of time and
community support (e.g., lack of interest from physicians) as well as insufficient
knowledge to engage in medication monitoring. The facilitators most frequently reported
were availability of ongoing professional training, communication and collaboration
between the school psychologist and prescribing physician, and inclusion of medication
monitoring activities on a student’s IEP.
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When examining the direction and strength of the relationship between various
demographic variables (e.g., degree level) and engagement in medication monitoring,
weak correlations were observed. This was also found when examining the relationship
between types of training reported in medication monitoring and frequency of engaging
in the practice. School psychologists did report engaging in medication monitoring for a
variety of disorders. The most frequent disorder was Attention Deficit/Hyperactivity
Disorder while the least frequent was Thought Disorders. When examining how well
demographic variables and types of training related to medication monitoring and
actually predict engagement in the practice, the results were not significant. Specifically,
the percentage of variance in medication monitoring accounted for by the demographic
and training variables was not significantly different than zero.
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Chapter Five
Discussion
Summary of the Study
The purpose of this study was to provide a comprehensive examination of the
current practices of school psychologists related to medication monitoring for the most
commonly prescribed psychotropic medications used with children and adolescents.
Specifically, this study examined the beliefs and practices of school psychologists related
to medication monitoring, such as the types and frequency of data collected, with whom
data are shared, and the types of training received related to medication monitoring.
Finally, this study examined the perceived facilitators and barriers to medication
monitoring in public schools by school psychologists.
This chapter will summarize the study results and discuss these findings with
respect to the extant literature. In addition, this chapter will discuss the implications of
the results for school psychologists, identify limitations of the study, and provide
directions for future research.
Research questions 1 and 2: Beliefs related to medication monitoring and
frequency of self-reported medication monitoring practices.
The purpose of these research questions was to determine the beliefs school
psychologists hold related to medication monitoring as part of their overall professional
activities as well as the relationship between those beliefs and actual medication
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monitoring practices. Findings from this study indicate the majority of respondents
(74.3%) “Agree” or “Strongly Agree” (M = 3.93, SD = 0.85) that medication monitoring
is an appropriate role for school psychologists.
The following definition for medication monitoring was used in the survey:
“Medication monitoring is defined as including the following activities (not an
exhaustive list); consultation with classroom teacher(s) and paraprofessionals, utilization
of behavior rating scales, behavior observations, review of work samples or curriculumbased assessments”. These findings are similar to extant research on this topic.
Specifically, Guereasko-Moore, DuPaul, and Power (2005) found the majority of
respondents to their survey also reported being in agreement that medication monitoring
is a practice in which school psychologists should be engaged. These findings indicate
that over time, the beliefs regarding medication monitoring among school psychologists
have remained relatively stable. However, it is important to note the samples were drawn
from different populations. Specifically, Guereasko-Moore et al. (2005) drew from a
national sample of 700 school psychologists who were members of the National
Association of School Psychologists (NASP) while the current study was based upon a
sample of 273 school psychologists who were members of the Florida Association of
School Psychologists (FASP).
School psychologists who reported “Agree” or “Strongly Agree” indicating their
endorsement of medication monitoring as a role in which they should be engaged
reported differing levels of practice. Specifically, school psychologists were asked to rate
the frequency in which they engage in medication monitoring for the previous school
year. However, when examining group differences among school psychologists who
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reported “yes” to the question asking if they have monitored medications at all over the
past school year and their beliefs regarding medication monitoring, statistically
significant results were obtained. Specifically, school psychologists who reported they do
engage in medication monitoring also reported perceiving this to be a needed role more
than those who did not report engaging (i.e., answered “no”) in medication monitoring.
Overall, the strength of the relationship between school psychologists’ beliefs regarding
medication monitoring and their actual reported practice was relatively weak. However,
school psychologists who reported engaging in medication monitoring also reported more
favorable beliefs regarding the practice than those who did not.
Several plausible hypotheses can be generated from these results. Specifically,
many school psychologists may agree that medication monitoring is an appropriate
professional role; however, they may not have time to engage in this practice. Extant
research found numerous barriers exist that prevent school psychologists from engaging
in roles outside traditional activities such as psychoeducational testing and assessment for
special education services (DuPaul & Carlson, 2005; Sulkowski, Jordan, & Nguyen,
2009). Additionally, school psychologists may agree medication monitoring is an
activity in which they should be engaged, but not have suitable training or tools to carry
out the practice. In the current study, school psychologists were asked to report barriers
to medication monitoring as well as facilitators. Many school psychologists reported lack
of time, insufficient training, and community support as reasons for not engaging in
medication monitoring. Previous research also reported similar findings. Specifically,
Carlson, Demaray, and Hunter-Oehmke (2006) conducted a survey examining multiple
facets of school psychologist’s practices related to medication monitoring. Not having
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sufficient training to engage in medication monitoring was found to be a significant
barrier as was having high caseloads which likely would result in insufficient time to
conduct these practices. The barriers and facilitators to medication monitoring will be
discussed in further detail later in this chapter.
Research Question 3: Current Medication Monitoring Practices of School
Psychologists.
This research question examined four facets of medication monitoring.
Specifically, it examined (a) the types of data collected when engaged in medication
monitoring, (b) the frequency of data collection, (c) the frequency with which data are
shared, and (d) with whom medication monitoring data are shared.
Findings indicate school psychologists utilize various types of data when engaged
in medication monitoring. Teacher rating forms, direct behavior observations, and
interviews were the preferred methods of medication monitoring data collection. In the
current study, respondents reported selecting methods of data collection that are sensitive
to small changes in performance over time compared to less sensitive measures (e.g.,
grades and annual state-wide standardized tests). Methods that allow for ongoing
progress monitoring such as behavior rating scales used in conjunction with direct
behavior observations were likely preferred due to their objectivity when used as a multimodal method of data collection. This speaks to the unique training school psychologists
possess which enables them to be well suited for the practice of medication monitoring.
Other researchers have advocated for school psychologists to engage in medication
monitoring to a greater extent due to their unique training (DuPaul & Carlson, 2005).
Specifically, these authors purport that many school psychologists are well-suited to
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assist in medication monitoring considering the following skills in their repertoire: (a)
training in data-based decision making; (b) training in systematic problem-solving
examining factors from an ecological perspective; (c) ability to progress monitor using
methods sensitive to small changes in performance; and (d) the ability to observe children
and adolescents in the school environment which typically is significantly different from
office-based settings or other community settings. Furthermore, previous research has
found the behaviors children and adolescents exhibit in non-school settings may be
dramatically different from the levels of behaviors exhibited in the classroom (Pelham et
al., 2000). Methods school psychologists used to collaborate will be discussed in further
detail later in this chapter.
Along with possessing unique training, school psychologists have at their disposal
a number of structured and standardized tools to use that are efficacious in the practice of
medication monitoring. For example, the use of structured direct behavior observation
tools such as the Behavior Observation System for Students (BOSS; Shapiro, 2010)
provides concrete data to evaluate academic engagement and off-task behaviors that may
be impacted by various dosage levels of psychotropic medications. In fact, research
supports the use of the BOSS for evaluating the effects of medications on students with
Attention-Deficit/Hyperactivity Disorder (ADHD). Specifically, Power, DuPaul,
Shapiro, and Kazak (2003) found this tool was efficacious in helping to determine the
impact of stimulant medications being used to treat the symptoms of ADHD.
In the current study, approximately half of the entire sample reported using some
method of data collection to engage in medication monitoring. This indicates school
psychologists are engaging in medication monitoring; however, the frequency in which
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they are monitoring the effects of medications is limited. Specifically, less than 1% of
respondents reported collecting medication monitoring data on a daily basis. It may not
be possible for many school psychologists to collect data daily given time and resource
constraints. Although it is recommended that during titration of a stimulant medication
careful monitoring occur to achieve the best dose-response relationship (DuPaul &
Carlson, 2005), this may not be feasible for most practicing school psychologists.

It

should be noted that this study did not differentiate between whether the school
psychologist or a delegate collected these data. Specifically, a paraprofessional, school
counselor, or classroom teacher may have collected data related to a student’s response to
medication and potentially shared it with the school psychologist. Additionally, this study
found a higher than average school psychologist to student ratio. This study found 38.9%
of the sample reported a school psychologist to student ratio of 1: >3,000.

When

comparing this ratio to the most recent data from the National Association of School
Psychologists membership survey, only 4% of school psychologists nationally reported
having a ratio of 1: > 3,000 (Curtis et al., 2010). As a result, due to their overall
caseloads it is possible school psychologists in the current study may have other members
of the school assist in collecting data related to medication monitoring. Future research
should explore this aspect of medication monitoring more in-depth.
The majority (i.e., 68%) of school psychologists reported using each of the
potential medication monitoring methods once per month or less. It is plausible that
school psychologists collect data regarding a child’s response to medication at regularly
scheduled times that occur once per month such as before a school-based intervention
team meeting. School psychologists reported direct behavior observations, child
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interviews, and teacher interviews as the most frequent methods to be used once per
week. Previous research found similar data collection methods to be viewed by school
psychologists as the most effective and feasible in the school setting (Guerasko-Moore, et
al., 2005). However, this study was limited to utilizing these data collection methods for
students with ADHD. The current study examined the use of the aforementioned data
collection methods for a wide variety of disorders. Future research should explore how
school psychologists integrate multiple sources of information when sharing data with
others (e.g., school-based intervention team, teacher, or prescribing physician).
The results varied with what entities school psychologists are sharing medication
monitoring information and the frequency with which they are engaging in this practice.
Specifically, the majority (66%) of school psychologists who reported collected these
data indicated that they share the data with others one time per month or less.
Approximately 15% of school psychologists reported sharing medication monitoring
information weekly with teachers. Also, 17.6% of school psychologists reported sharing
medication monitoring information bi-weekly at school-based intervention team
meetings. Lastly, a small percentage of school psychologists reported daily sharing of
information with the teacher (2.7%) and school based-intervention team (1.4%). With
respect to the prescribing physician, school psychologists, on average, reported sharing
information approximately one time per month or less (52%). This is consistent with
previous research. Specifically, Carlson, Demaray, and Hunter-Oehmke (2006) found in
a study examining school psychologists’ caseloads in which students were receiving
medications that 62% of school psychologists reported working with physicians to
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evaluate medication trials for children but the collaborative monitoring was infrequent
(e.g., < 1 time per month).
When examining the frequency in which medication monitoring information is
shared, it is hypothesized that medication monitoring data are shared with teachers and
other staff at regularly scheduled meetings in which a discussion of the identified child is
already taking place. Sharing of information with prescribing physicians occurs less
frequently due to barriers in communication and collaboration. Extant research has found
physicians are unsure with whom to communicate or how to forge alliances with the
educators including school psychologists (Bradley-Klug et al., 2010). Additionally,
Bradley-Klug et al. (2010) found physicians reported first attempting to collaborate with
the school nurse and classroom teacher, rather than the school psychologist. Future
research should examine more specific methods school psychologists and physicians
would find effective and feasible to communicate on a more frequent basis.
Research Question 4: Types of Training School Psychologists Receive in the Practice
of Medication Monitoring.
Sixty-three percent of respondents reported receiving training related to
medication in the past. In-service training, professional conferences, and personal
reading of scholarly articles were reported to be the most frequent avenues through which
school psychologists received this training. In comparison, Carlson and colleagues
(2006) examined school psychologists’ practices related to medication monitoring and
found the majority of school psychologists have not had formal university training in
child psychopharmacology (81%). The primary method school psychologists acquired
background knowledge in child psychopharmacology was through professional

98

workshops (88%) and independent reading (96%). In contrast to the Carlson et al. study,
45% of respondents in the current study indicated they had some type of training related
to medication monitoring as a component of a graduate course. Carlson et al. (2006)
examined this aspect of training and found only 19% of respondents reported graduate
coursework containing a component that includes topics related to medication
monitoring. As will be discussed later in this chapter, the elapsed time between studies,
increased attention towards psychotropic medications being taken by children, and
evolving school psychology training programs may contribute to the differences in
findings.
With respect to personal reading of scholarly articles as well as other sources of
information (e.g., textbooks), a wide range was reported from 0-100 hours of time spent
reading on the topic. A number of hypotheses are offered to explain these findings.
School psychologists are required to participate in a variety of trainings and in-service
presentations each year in most districts. Additionally, school psychologists who hold a
Nationally Certified School Psychologist (NCSP) credential are required to obtain
National Association of School Psychologists (NASP) approved continuing education
units (CEUs) every three years. It is possible that school psychologists who hold the
NCSP seek training in medication monitoring through the resources offered by NASP.
Future research examining this hypothesis would need to draw upon a stratified national
sample.
This study found a higher percentage of school psychologists reporting training in
medication monitoring than previous research. Specifically, Guerasko-Moore et al.
(2005) found 41.9% of school psychologists reported receiving training in medication
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monitoring compared to 63.3% in the current study. It is hypothesized because this
current study was conducted six years after the original study, the number of training
opportunities available to school psychologists regarding the importance of medication
monitoring have increased. Factors such as polypharmacy (Bush, 2006) and the overall
increase in the number of school age students prescribed medication (Lam, & CollierCrespin, 2003; Aman, Lam, & Van Bourgondien, 2005; Witwer & Lecavalier, 2006) may
also contribute to increased training opportunities for school-based personnel.
Another important hypothesis is related to where each sample was drawn. The
study by Guerasko-Moore et al. (2005) was based on a national sample of 700 school
psychologists who were members of NASP. The current study included a sample of 375
members of FASP. The demographics of each sample are inherently different. It is
possible that the training opportunities offered in Florida are different than what may be
available elsewhere in the nation.
Overall, respondents report receiving training in medication monitoring and report
a variety of sources to obtain this training. Future research could examine the
opportunities available at professional conferences that offer training on medication
monitoring in the schools. Additionally, future research could examine the types of
training that prepare school psychologists to most competently engage in medication
monitoring. Examining the modalities and preferences for training on this topic could be
yet another research avenue in the future.
Research Question 5: Perceived Facilitators and Barriers to Medication Monitoring
Respondents reported a number of factors that facilitate the practice of medication
monitoring. Professional training on medication monitoring was most frequently
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reported by respondents as a facilitator to increasing the probability that a school
psychologist would engage in this practice. Also, collaboration among school
psychologists and other professionals (e.g., prescribing physician, teachers, and parents)
was cited as an important facilitator. Extant research on collaboration among school
psychologists and other professionals supports this as an important facilitator for other
activities such as collaborating among school psychologists and other professionals to
create a wrap-around support system of care for students receiving services from multiple
entities (Carlson, 2008; Drotar, Palmero & Berry, 2004). In fact, creating more cohesive
systems of care is advocated as the first step in effective medication monitoring (Wodrich
et al., 1999).

Additionally, enhancing communication and collaboration between

school-based personnel and medical entities can improve overall wrap-around services
for children and adolescents. For example, research has found problems related to
adherence with medication regimens occurs due to a myriad of factors such as intolerable
side effects and misunderstanding of the need to regularly take medication (Bussing,
Koro-Ljungberg, & Gary, 2005; Gau, Chen, & Chow, 2008). Because many
medications are taken to improve symptoms of disorders that may impact both academic
and social functioning, school personnel can also be part of the overall team that helps
educate children and families about the importance of adhering to medication regimens as
part of an overall home-school partnership.
A number of respondents suggested integrating medication monitoring as a
practice on students’ Individualized Education Plans (IEP) as a method to facilitate the
practice of medication monitoring. This would also likely enhance a cohesive system of
care for children and adolescents. Time needs to be set aside for the school psychologist
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to collect data and communicate with outside parties. Obtaining easy to use checklists or
other data collection methods were also listed as an important facilitator to medication
monitoring. There are a number of tools available that would be useful in the practice of
medication monitoring. For example, the BOSS (Shapiro, 2011) is sensitive to small
changes in behavior that would directly bear a relationship to students who are being
titrated for a medication or who may be experiencing negative side effects (e.g.,
drowsiness) impacting academic functioning. Additionally, as previously mentioned,
tools such as the BOSS have been shown to be effective in helping to determine the right
dosage for stimulant medications for a particular child (Power et al., 2003). This is
important as the same dosage of a medication can have dramatically different effects on
different children (Christensen, Helms, & Chesney, 1999). Having more time via fewer
students on school psychologists’ caseloads was also reported to facilitate medication
monitoring. The current study found 38.9% of school psychologists reported a school
psychologist to student ratio at or exceeding 1:3,000. NASP recommends a school
psychologist to student ratio of no more than 1: 2,500 (Curtis et al., 2010). Thus,
respondents to this survey have higher school psychologist to student ratios than is
recommended by NASP.
This study found differences compared to previous research with respect to
facilitators for medication monitoring. Specifically, Guerasko-Moore et al. (2005) found
teacher support to be the strongest facilitator for medication monitoring. This particular
facilitator was not reported by respondents in the current study. One hypothesis is that the
current study employed an open-ended question format regarding facilitators in contrast
to the forced-choice question on the survey related to barriers. It is possible school
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psychologists did not consider teacher support as a facilitator to medication monitoring
due to the way the question was structured. It is hypothesized that respondents may have
not fully understood this question or may have not completely answered it due to its
location on the survey as the last question.
This study found no predictive relationship between a number of variables (i.e.,
degree level, geographic location, types of training, and training program philosophy) and
whether a school psychologist engages in medication monitoring. It is likely a number of
other factors not examined in this study are related to whether a school psychologist
engages in this practice. The predictive nature of various variables and their effects on
school psychologist’s medication monitoring practices will be discussed later in this
chapter.
With respect to barriers to medication monitoring, respondents reported a number
of factors that inhibit their efforts to engage in this practice. Lack of time was reported
as the largest barrier. This finding is consistent with previous research. Specifically,
Guerasko-Moore et al. (2005) found time was the largest barrier to medication
monitoring. Lack of community support (e.g., physicians and other providers) was listed
as the second largest barrier in the current study. Insufficient knowledge about
medication monitoring or methods to engage in the practice was listed as the third largest
barrier. Interestingly, a number of respondents utilized the “Other” category to write in
their own barriers. Responses included concerns that pediatricians prescribe the most
amount of psychotropic medications yet have the least amount of training compared to
other medical professionals was listed as a barrier. Extant research has found that the
vast majority of psychotropic medications are indeed prescribed by primary care
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physicians rather than specialists (i.e., child and adolescent psychiatrists), particularly in
rural areas (Bush, 2006). It is likely that pediatricians are unaware of the skills a school
psychologist may possess or how to collaborate with them for activities including
medication monitoring. Bradley-Klug and colleagues (2010) examined pediatricians’
perceptions of school psychologists’ roles. Pediatricians reported being largely unaware
of school psychologists’ training, indicated misperceptions about their role within public
schools, and being unsure of with whom to communicate at the school regarding a child
in their care. Future research should examine how to minimize barriers school
psychologists listed such as time and insufficient training along with the most effective
methods school psychologists could use to forge relationships with not only primary care
pediatricians but other professionals such as therapists and child/adolescent psychiatrists.
Examining methods to increase a cohesive system of care related to ongoing professional
communication and collaboration among school psychologists and other professionals
would be another important research avenue.
Research Question 6: Direction and Strength of the Relationship Between
Geographic Location, Degree Level, Training Program Philosophy, Type of School
Served, Types of Training Related to Medication Monitoring, and Frequency of
Medication Monitoring by School Psychologists.
This research question examined the interrcorrelations between the school
psychologists’ geographic location, degree level, training program philosophy, type of
schools served, types of training related to medication monitoring, and the frequency
school psychologists engage in medication monitoring. Overall, small to moderate
significant positive correlations were found for some variables. Specifically, school
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psychologists who reported practicing in a rural school setting (rs = 0.39) and who
received in-service training (rs = 0.38) were the only significant positive correlations. A
significant moderate negative correlation was found for school psychologists who
reported spending some of their time in a non-student allocation (rs = -.43).
Several hypotheses could explain the lack of significant relationships between the
variables examined other than those previously mentioned. First, the variables selected
were chosen based on an a priori decision of which variables may potentially be related
to school psychologists’ practice of medication monitoring. It is possible other variables
not examined in this study may be more closely related such as school psychologist to
student ratio, years practicing as a school psychologist, and specific facilitators that
enable a school psychologist to engage in medication monitoring. Second, this study
utilized an overall sample size of 240 respondents. However, for this particular research
question, only 77 were included in the analyses as only data from respondents who
indicated they do engage in medication monitoring practices were included in the
analyses. Therefore, the relatively small sample size may have impacted the results. A
larger nationally representative sample may produce different findings than the current
study. An additional possible reason could be that the variables examined truly are not
related to the degree to which a school psychologist monitors medications. That is,
students are taking medications at all grade levels and geographic locations across the
U.S. based on previous prevalence research (Abrams, Flood, & Phelps, 2006; Zito, 2003).
Also, although it was hypothesized that school psychologists trained at the doctoral level
would have more specialized coursework containing components related to medication
monitoring, it is possible this is not the case. Training programs may integrate topics

105

related to medication monitoring throughout coursework, regardless of degree level. It
was also hypothesized that training programs which are more intervention focused than
assessment focused would incorporate components related to medication monitoring at
greater rates. It is possible this is also not occurring in practice. Overall, the relatively
weak relationships found should be examined more closely in future research as a larger
sample size and examining different interrelationships between variables could yield
more significant results.
Additional Information: Predictors of Medication Monitoring
Significant results were not obtained predicting medication monitoring practices
by a variety of demographic, training, graduate program philosophy, and degree level
variables. Some specific survey items needed to be removed from the regression model
due to having a low n. Additionally, some variables had to be combined (e.g., types of
training) in the analyses due to violations of the assumptions for a multiple regression
analysis. The overall sample size for this question was 51, and several respondents’ data
had to be eliminated due to falling outside of acceptable ranges for a multiple regression
analysis (i.e., Mahalanobis distance exceeding cutoff). Therefore, on one hand it is
plausible the independent variables examined (i.e., degree level, training program
philosophy, type of school served, and types of training reported) were not predictive of
whether a school psychologist engages in medication monitoring. As was found when
examining the intercorrelations between demographic, training program philosophy, type
of schools served, and degree level, there simply may not be a strong relationship
between these variables as well as there not being a single variable that predicts whether
a school psychologist is going to engage in medication monitoring. Alternatively, it is
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possible due to limitations with this study’s sample size that significant results could not
be obtained. Future research should examine what factors are truly predictive of school
psychologists’ engagement in medication monitoring at a number of levels. First,
replicating this study would further answer whether there are factors that predict if a
school psychologist engages in medication monitoring. Second, examining the multitude
of other facets that could be predictive (e.g., assignment to a center school specializing in
educating children with behavior disorders) of a school psychologist engaging in
medication monitoring could also further determine if there are other factors predicting
school psychologists’ engagement in medication monitoring. Lastly, examining the
relationship between the school psychologist to student ratio as part of an overall multiple
regression analysis that includes other demographic variables may glean new interesting
information and significant results.
Additional Information: Types of Disorders for which School Psychologists Monitor
Medications
The current study sought to build on previous research examining medication
monitoring practices of school psychologists for stimulant medications utilized to treat
the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD; Guerasko-Moore et
al., 2005). One facet of the current study was to examine other disorders of youth for
which school psychologists may be monitoring medications. Respondents were asked on
the following scale how many students per disorder they have monitored in the past
school year: (0 = no students), (1-2 = one-two students), (3-5 = three to five students),
(6-8 = six to eight students), and (9+ = nine or more students). The scale for the category
“Other” was free response in case there were disorders for which school psychologists
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were involved in medication monitoring that were not listed. The disorders which were
listed included Attention-Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder,
Depressive Disorders, Anxiety Disorders, Autism Spectrum Disorders, Asperger’s
Disorder, Bipolar Disorder, Tourette’s Syndrome and/or Tic Disorders, Thought
Disorders (e.g., schizophrenia), Multiple Disorders (e.g., intellectual disability and
disruptive behavior disorder), and a category for “Other Disorders” in which respondents
were asked to write in the name of the disorder.
The results of this study indicate school psychologists are monitoring medications
for a variety of disorders. Although it is not surprising that ADHD was reported as the
most frequent disorder in which medication monitoring occurred, other disorders were
also prevalent albeit at lower rates. The disorders for which school psychologists
reported monitoring medications are listed from most to least frequent: ADHD,
Oppositional Defiant/Conduct Disorder, Autism Spectrum Disorders, Depressive
Disorders, Anxiety Disorders, Bipolar Disorder, Multiple Disorders, Asperger’s Disorder,
Tourette’s Syndrome and/or Tic Disorders, and Thought Disorders. The results indicate
school psychologists are monitoring medications for a variety of disorders but on average
for 1-2 students per year.
Overall, the results of this research question provide interesting new data. As
previously noted, this study sought to expand on previous research which examined
medication monitoring practices of school psychologists limited to students with ADHD.
This study found a multitude of disorders for which school psychologists are monitoring
medications. Previous research found 39% of children and adolescents receiving special
education services were prescribed a psychotropic medication to inhibit externalizing
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behaviors and 17% of those students were administered multiple medications (Mattison,
1999).
These findings build upon previous research in determining what other disorders
of youth school psychologists may be monitoring medications. To date, no extant
research has examined this topic. Future research could look at a myriad of other factors
that facilitate or inhibit school psychologists from monitoring medications for various
disorders. Additionally, it would be interesting to know what types of methods school
psychologists use for each type of disorder. Potentially interviewing school
psychologists about how they monitor medications for specific disorders (e.g.,
externalizing vs. internalizing) along with what tools they feel are most effective and
feasible for each particular disorder would likely yield interesting new information.
Implications for Practice: Facilitating Medication Monitoring Practices
Findings from this study build on previous research and underscore the need for
school psychologists to engage in medication monitoring in certain situations.
Significant numbers of children are attending school while being prescribed a number of
psychotropic medications aimed at treating symptoms that frequently inhibit school
performance. For example, Mattison (1999) found over one third of students receiving
special education services in public schools are prescribed a psychotropic medication and
a quarter of those are prescribed multiple medications to treat externalizing behavior
problems. Many of the medications being prescribed to children and adolescents have
not had substantial research conducted on their effects in children (Bush, 2006).
Furthermore, the practice of off-label prescribing along with the fact that children are
being prescribed medications by multiple professionals further demonstrates a need to

109

monitor. Specifically, given the findings that many children are prescribed various
psychotropic medications for the purposes of treating symptoms that primarily occur in
the school setting (DuPaul & Carlson, 2005), medication monitoring is a necessary role
for school psychologists.
The results of this study indicate most school psychologists are in agreement and
feel medication monitoring is a necessary role. However, a number of barriers exist as
found in the current study. Specifically, time was reported as a major barrier.
Advocating for allocated time to conduct activities related to medication monitoring,
writing into IEPs the need to conduct monitoring of the child’s response to medication,
and communication with the prescribing physician will alleviate some of the barriers
reported in this study. Additionally, as most practitioners in the field of school
psychology hold a specialist degree or equivalent, integrating coursework into both the
doctoral and specialist level training programs may increase future practitioner’s
awareness of methods to engage in medication monitoring. Many programs train
practitioners to use methods such as direct behavior observation augmented with tools
such as the BOSS (Shapiro, 2010) as well as utilizing a collaborative consultation model
with school personnel. These skills practitioners possess make them well suited to
engage in medication monitoring when provided with the knowledge of how and time to
do so.
Given the extant research on barriers to communication and collaboration with
physicians as well as school psychologists (Bradley-Klug et al., 2010), it is important to
continue to address and reduce barriers to creating a bi-directional system of care for
children who may be prescribed multiple psychotropic medications and are experiencing
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adverse side effects. Helping parents to learn to trust school personnel and fostering a
partnership to benefit the child along with permission for the school psychologist and
prescribing physician to engage in communication will help alleviate some of the barriers
to medication monitoring.
Finally, as children increasingly are prescribed multiple medications and the
demands in the classroom increase, teachers may not notice subtle changes in children
that could be the result of a negative side effect to a medication. School psychologists
with the knowledge and skills to assess small changes in behavior or academic
performance may be able to educate teachers on strategies to identify problems a child is
experiencing related to medication side effects. Using a systematic problem-solving
approach, school psychologists can assist teachers and other educators to hypothesize
causes for poor academic performance that may be related to psychotropic medication.
Limitations
This study has several limitations that should be considered when interpreting the
results. A total of 140 usable surveys were included in the analyses to answer each
research question with a notable exception. Respondents who indicated they had not
engaged in medication monitoring over the past school year were directed to skip a
number of questions. Not all participants reported engaging in medication monitoring.
As a result, some research questions were analyzed with a smaller total sample (i.e., 77
respondents). This may have affected the significance of some of those analyses,
particularly the predictive analyses.
Although this study resulted in a relatively high response rate of 61%,
generalization of the results is restricted by the use of a convenience sample. The sample
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was drawn from the FASP membership database representing only school psychologists
practicing in the State of Florida. It also is irrespective of whether the school
psychologists are also members of NASP or hold a NCSP credential. As a result, there
are specific threats to ecological validity which affects the degree to which a researcher
can generalize findings across settings or to other situations (Johnson & Christensen,
2004). Another potential threat to the results of this study is population validity. This
refers to the degree to which a researcher can generalize the findings to other groups
(Johnson & Christensen, 2004). As previously mentioned, this study employed a
convenience sample of school psychologists practicing in the State of Florida. The
results of this study cannot be generalized outside of the population used in the study and
also must be cautiously compared to previous research as other studies on this topic
referenced in this chapter utilized a different study population.
There is a possibility that responses obtained do not accurately reflect the
practices of school psychologists engaged in medication monitoring. The construct of
social desirability bias may affect the results (Dillman, Smyth, & Christian, 2009).
Specifically, respondents may assume the researcher wants them to engage in medication
monitoring practices and may overestimate their practices as a result. Additionally, this
study utilized an up-front incentive format in which each participant was given a dollar
bill enclosed in the survey as an incentive for participation. Respondents may have felt
indebted to the researcher due to receiving a tangible reward upfront and mistakenly
reported engaging in medication monitoring when in fact they do not. Consistent with
social exchange theory, the cost to the respondent was kept to a minimum by utilizing a
brief (e.g., 15-20 minute completion time) survey and providing a self-addressed stamped
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envelope in which to return it based on recommendations from Dillman et al. (2009). In
order to minimize the probability of this occurrence, the survey methodology utilized an
anonymous design along with pilot testing the survey with 26 school psychologists which
produced clear and concise operational definitions of medication monitoring as well as
clearly worded questions.
Future Directions
This study was the first to examine the medication monitoring practices of school
psychologists for a wide variety of psychotropic medications prescribed to youth. The
findings of this study inform both the literature and practice at the pre-service and inservice levels. However, because this study was the first to address these topics, it should
be replicated with a larger more representative sample of school psychologists. There are
a number of possible future directions to be considered based upon the outcomes of this
study. . Examining specific types of training at the pre-service and in-service levels
could help inform what types of training are most useful to school psychologists who
wish to engage in medication monitoring. Developing standard protocols for use in
school districts to assist teachers, paraprofessionals, and school psychologists with
medication monitoring would likely help increase this practice. Assessing other school
personnel such as administrators’ beliefs regarding medication monitoring would be
another likely avenue for future research. Further examining pediatricians, child and
adolescent psychiatrists, neurologists, and other non-physician providers’ beliefs
regarding medication monitoring would also be helpful. Determining new methods to
collaborate and communicate as well as what types of information (e.g., concise reports)
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are most beneficial to both the school psychologist and prescribing physician will be
informative.
Final Thoughts
Although it is largely believed that medication monitoring is an important role for
school psychologists, more research on how to effectively monitor a child’s response to
medication is needed. More than half of the school psychologists in this study reported
engaging in some form of medication monitoring. A number of barriers were reported
that currently limit the ability to collect data and inhibit the frequency of data collection
and monitoring. Respondents offered feedback regarding facilitators that would enhance
the ability of the school psychologist to engage in medication monitoring. Future
research is necessary to further explore this topic and to assist in the development of
strategies to promote medication monitoring as a role for school psychologists.
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Appendix A
Cover Letter to Participants

School Psychologists’ Practices of Psychotropic Medication Monitoring
Dear FASP Member,
You have been selected as a current FASP member to participate in a research study
examining the role of school psychologists in medication monitoring of students. The goals
of this study are to determine the types of psychotropic medications (e.g., Adderall,
Clonidine, Risperidone) school psychologists monitor, how the effects of medications are
evaluated, with whom monitoring data are shared (e.g., teachers, parents, physicians), and
the barriers to and facilitators of medication monitoring in our schools. Findings will
inform both pre-service and in-service training on this important topic.
You are being asked to be part of this study because you are a practicing school
psychologist whose primary employment is in a school setting. If you do not currently
work in a school setting, please check the box on the front of the survey and return it in the
postage paid envelope. We would like you to be a participant in this study, regardless
of the amount of time you currently spend monitoring psychotropic medications. The
survey will only take 10-15 minutes to complete and we have provided you with a
postage-paid envelope to use in returning the survey. Participation is completely
voluntary and involves completing the enclosed questionnaire and returning it in the
enclosed envelope within 2 weeks. Your participation will be anonymous. A completed
and returned survey will be considered consent to participate in the study. Should we
publish or disseminate findings from this study, only aggregate data will be published. As
a token of our appreciation for participating in this study, a dollar bill is enclosed to
use for coffee, snack, or anything you wish.
This study was approved by the University of South Florida Institutional Review Board
(IRB # Pro00002616) and the Florida Association of School Psychologists. “The Florida
Association of School Psychologists encourages school psychologists to participate in
the completion of surveys which increase the knowledge base about the practice of
school psychologists in the state of Florida. This survey has been approved by the
Research Committee and FASP Executive Board”.
Thank you in advance for your time and assistance with this research study. If you have
any questions or concerns about the study, please feel free to contact us at the numbers or
emails listed below. We also invite you to contact us if you would like to obtain the
results of the study as soon as they are available. If you have questions about your
rights as a participant in this study, general questions, or have complaints, concerns or
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issues you want to discuss with someone outside the research, call the USF IRB at (813)
974-5638.
Thank you so much for your participation.
Sincerely,
Jason Hangauer, Ed.S, NCSP
Principal Investigator-Doctoral Candidate
Associate Professor
School Psychology Program
University of South Florida
jhangaue@health.usf.edu
(813) 974-0605

Kathy Bradley-Klug, Ph.D, NCSP
Chairperson of Dissertation ResearchSchool Psychology Program
University of South Florida
kbradley@usf.edu
(813) 974-9486

124

Appendix B
Follow-up Letter to Participants

School Psychologists’ Practices of Psychotropic Medication Monitoring
Dear FASP Member,
You have been selected as a current FASP member to participate in a research study
examining the role of school psychologists in medication monitoring of students. The goals
of this study are to determine the types of psychotropic medications (e.g., Adderall,
Clonidine, Risperidone) school psychologists monitor, how the effects of medications are
evaluated, with whom monitoring data are shared (e.g., teachers, parents, physicians), and
the barriers to and facilitators of medication monitoring in our schools. Findings will
inform both pre-service and in-service training on this important topic.
Our records indicate that as of this date, we have not received a completed
questionnaire from you. Please take a few minutes to complete and return the enclosed
survey in the postage paid envelope. The survey will only take 10-15 minutes to
complete. We would like you to be a participant in this study, regardless of the amount of
time you currently spend monitoring psychotropic medications. If you do not work in a
school setting at all, please check the box on the front of the survey and return it in
the postage paid envelope.
Your participation will be anonymous. A completed and returned survey will be
considered consent to participate in the study. Should we publish or disseminate findings
from this study, only aggregate data will be published. As a token of our appreciation
for participating in this study, a dollar bill was enclosed in the first copy of the survey
you received to use for coffee, snack, or anything you wish.
This study was approved by the University of South Florida Institutional Review Board
(IRB # Pro00002616) and the Florida Association of School Psychologists. “The Florida
Association of School Psychologists encourages school psychologists to participate in
the completion of surveys which increase the knowledge base about the practice of
school psychologists in the state of Florida. This survey has been approved by the
Research Committee and FASP Executive Board”.
Thank you in advance for your time and assistance with this research study. If you have
any questions or concerns about the study, please feel free to contact us at the numbers or
emails listed below. We also invite you to contact us if you would like to obtain the
results of the study as soon as they are available. If you have questions about your
rights as a participant in this study, general questions, or have complaints, concerns or
issues you want to discuss with someone outside the research, call the USF IRB at (813)
974-5638.
125

Thank you so much for your participation.
Sincerely,
Jason Hangauer, Ed.S, NCSP
Principal Investigator-Doctoral Candidate
Associate Professor
School Psychology Program
University of South Florida
jhangaue@health.usf.edu
(813) 974-0605

Kathy Bradley-Klug, Ph.D, NCSP
Chairperson of Dissertation ResearchSchool Psychology Program
University of South Florida
kbradley@usf.edu
(813) 974-9486
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Appendix C
Survey
School Psychologists’ Practices of Psychotropic Medication Monitoring

If you work in a school part- or full-time, please continue. If you DO NOT work in a school
setting at all, please DISCONTINUE at this point, check the box below, and return the survey in
the enclosed return envelope.
I do not currently work in a school.
SECTION 1: BACKGROUND INFORMATION
Please respond to all items based on your school practice for the 2010-2011 school year.

1.

Gender (Circle one)

2.

Ethnicity (Circle one)
A. Black/African American
C. Native American/Alaskan Native
E. Hispanic American/Latino
B. Asian American/Pacific Islander
D. White/Caucasian F. Other _____________

3.

State in which you are currently employed (e.g., FL, NY, CA) _____________

4.

Job Status (circle one)
A. Full-time employee
Contractual/independent consultant

5.

Highest degree earned in School Psychology (circle one)
A. Bachelor’s B. Master’s C. Master’s +30 D. Specialist

6.

A. Female

B. Male

B. Part-time employee C.

E. Doctorate

Highest graduate degree earned NOT in school psychology: please specify degree (e.g., None,
Doctorate)____________
and the area in which degree was earned (e.g., Educational Leadership) ____________________

7.

Years practicing as a school psychologist (post-degree, including present year) _____________

8.

The approximate number of students you serve (school psychologist: student ratio)
____________

9.

Number of buildings that you currently serve _____________________

10. Primary location of current work site (please choose one):
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Urban ________Suburban________

Rural ________

11. Currently, what percentage of your time is spent working with students in these grade categories?
Please make sure your percentages total 100%.
Pre-K: _________ K-5: _________6-8: ________9-12: ___________ Non-student
allocation________

SECTION 2: Medication Monitoring Training
12. Have you received any type of training at any time in the past on monitoring students taking
psychotropic medications?

Definition of Medication Monitoring:
Medication monitoring is defined as including the following activities (not an
exhaustive list): Consultation with classroom teacher(s) and paraprofessionals,
utilization of behavior rating scales, behavior observations, review of work
samples, or curriculum-based assessment. If there are activities not listed that
you engage in which you believe are considered medication monitoring, please
make a note of it in the space below, it will be very helpful information on this
important topic.
Additional medication monitoring
activities:__________________________________________________________________________

Yes

A. In-Service Trainings
(with some component
devoted to medication
monitoring)
B. Online Trainings

If Yes, please circle the type(s) of
training received. If
No, please move onto question #13

No

Number of trainings =______

N/A (I have not attended
in-service trainings on
this topic)

Number of trainings =______

N/A (I have not attended
online trainings on this
topic)

Number of professional
conferences =______

N/A (I have not attended
professional conferences
on this topic)

C. Professional Conferences
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D. Graduate courses with a
component focused on
psychotropic medications
E. Personal reading of scholarly
journals focused on
monitoring psychotropic
medications
F. Personal reading (e.g.,
textbooks, other sources on
monitoring psychotropic
medications)
G. Other (Please describe)

N/A (I have not taken
courses with a component
focused on this topic)

Number of courses = ______

Number of hours spent reading
= ______

N/A (I have not read
scholarly articles focused
on this topic)

Number of hours spent reading
= ______

N/A (I have not read
textbooks or other sources
focused on this topic)

Number of hours spent =
________
Describe
activity____________________
__________________________

N/A (I have not spent
other time on this topic
not already included)

13. What was the overall philosophy of your school psychology training program (e.g., courses,
practicum, internship)?
(Circle one):
Primarily
Somewhat
Balanced Between
Somewhat
Primarily
Assessment
Assessment
Assessment and
Intervention
Intervention
Focused
Focused
Intervention Focused
Focused
Focused
1

2

3

4

5

14. Please indicate your opinion of this statement:
Monitoring the effects of psychotropic medications for students with emotional and behavior disorders
(e.g.,ADHD, depression, anxiety) and other disorders is a role in which school psychologists should be
involved.
Strongly
Disagree

Disagree

Neither Agree nor
Disagree

Agree

Strongly Agree

1

2

3

4

5

15. Have you been involved in monitoring the effects (beneficial or negative) of a psychotropic
medication in any manner for a student with whom you work? (See definition of medication
monitoring broadly defined at question #12)

Yes

No

If Yes, move to question #16, If No, please move to question #21.
16. How frequently do you monitor the effects (beneficial or negative) of a psychotropic medication
for students with whom
you work? (Circle one):
Annually

Quarterly (i.e., fall,
winter, spring)

Once per
month

Once per
week
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Daily

2-5 Times
per day

5+ Times
per day

1

2

3

4

5

6

7

17. In the past year, how many students have you monitored for the effects (beneficial or negative) of
a psychotropic medication in any manner? (Circle one):
0

1-2

3-5

9-11

6-8

12-14

15+

18. In the last year, approximately how many students have you monitored for the effects of
psychotropic medications for each of the following disorders (if known)?
Disorder

Number of students for whom medication
monitoring data were collected in the past
year

A. Attention-Deficit/Hyperactivity Disorder
(ADHD)

0

1-2

3-5

6-8

9+

0

1-2

3-5

6-8

9+

N/A

C. Depressive Disorders

0

1-2

3-5

6-8

9+

N/A

D. Anxiety Disorders

0

1-2

3-5

6-8

9+

N/A

E. Autism Spectrum Disorders

0

1-2

3-5

6-8

9+

N/A

F. Aspergers Disorder

0

1-2

3-5

6-8

9+

N/A

G. Bipolar Disorder

0

1-2

3-5

6-8

9+

N/A

H.Tourettes Disorder and/or Tic Disorders

0

1-2

3-5

6-8

9+

N/A

I. Thought Disorders (e.g., schizophrenia)

0

1-2

3-5

6-8

9+

N/A

J. Multiple Disorders (e.g., mental retardation and
disruptive behavior

0

1-2

3-5

6-8

9+

N/A

0

1-2

3-5

6-8

9+

N/A

B. Oppositional Defiant Disorder, Conduct
Disorder or

N/A

any other externalizing disorder

Disorders)

K. Other Disorders (please write in below)

19. When you do engage in medication monitoring, in general with whom and how often do you share
the information?
About

Less
Sharing of information

A. Parents

than 1x
month

Once
1x month

Every
2 Weeks

1

2
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3

1x a
week

4

N/A
Daily

5

Or 0 times

N/A

B. Teacher

1

2

3

4

5

N/A

C. Prescribing Physician

1

2

3

4

5

N/A

D. School-based intervention team
(multiple individuals)

1

2

3

4

5

N/A

1

2

3

4

5

N/A

E. Other (please specify below)
______________________________

20. Please indicate how often you have used the following procedures to monitor the effects of
psychotropic medications on students:
About

Less
Procedure

than 1x

1x

month

month

Once
Every
2 Weeks

1x a
week

Daily

N/A
Or 0 times

A. Teacher rating forms (e.g., Child
Behavior Checklist, Behavior
Assessment Scale for Children)

1

2

3

4

5

N/A

B. Direct behavior observations

1

2

3

4

5

N/A

C. Parent rating forms (e.g., Child
Behavior Checklist, Behavior
Assessment Scale for Children)

1

2

3

4

5

N/A

D. Parent interviews

1

2

3

4

5

N/A

E. Child self report via rating scale
(e.g., CBCL, Children’s Depression
Inventory, Reynolds Children’s
Manifest Anxiety Scale)

1

2

3

4

5

N/A

F. Child interview

1

2

3

4

5

N/A

G. Teacher interview

1

2

3

4

5

N/A

H. Permanent products (e.g., work
samples)

1

2

3

4

5

N/A

I. Curriculum based assessment

1

2

3

4

5

N/A

J.Grades

1

2

3

4

5

N/A

K. Other (please specify in the space
below)

1

2

3

4

5

N/A

_______________________________

21. To what extent do you agree or disagree that each of the following factors is a barrier to school
psychologists monitoring psychotropic medications students are taking?
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Factor
A. Lack of Time

Strongly
Disagree
1

Disagree
2

Neither Agree
nor Disagree
3

Agree
4

Strongly
Agree
5

B. Insufficient Knowledge
(e.g., how to monitor
medications and/or training
on medication monitoring)

1

2

3

4

5

C. Lack of Resources (e.g.,
availability of rating scales
and communication with
outside providers).

1

2

3

4

5

C. Lack of Teacher Support

1

2

3

4

5

D. Lack of Support of other
colleagues (e.g., schoolbased student assistance
team members)

1

2

3

4

5

E. Lack of Parent Support
(e.g., parent
permission/cooperation)

1

2

3

4

5

1

2

3

4

5

G. Lack of Support of school
psychologist’s supervisor

1

2

3

4

5

H. Teacher Availability (e.g.,
for consultation, progress
monitoring, review of work
samples)

1

2

3

4

5

1

2

3

4

5

E. Lack of School-based
administrative support
(e.g., principal and vice
principal)

I.

J.

Lack of Community
Support (e.g., collaborative
relationships with
mental/physical health
providers in the
community)
Other Barriers not listed
above (please write in)
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22. Given the listing of potential barriers in the previous question, please list what you feel may be a

facilitator to school
psychologists monitoring psychotropic medications:
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
Lastly, please use the space below to add any comments about this topic or survey:
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________
______________________________________________________________________________________

______________________________________________________________________________

End of Survey. Thank you!
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